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“E os marinheiros, perguntou ela, […], Disseram-me que já não há ilhas 
desconhecidas, e que, mesmo que as houvesse, não iriam eles tirar-se do 
sossego dos seus lares e da boa vida dos barcos de carreira para se 
meterem em aventuras oceânicas, à procura de um impossível, como se 
ainda estivéssemos no tempo do mar tenebroso, E tu, que lhes 
respondeste, Que o mar é sempre tenebroso” 
 
(J. Saramago, O conto da Ilha Desconhecida) 
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PREFACE	  
 
A series of large population studies revealed the existence of a strong inverse correlation 
between plasma levels of high-density lipoprotein cholesterol (HDL·C) and cardiovascular 
risk. This inverse relation is observed at the level of low-density lipoprotein cholesterol, 
including very low concentrations achieved in statin-treated patients [Barter, 2007a]. The 
central role of HDL in reverse cholesterol transport (RCT), the process by which cholesterol is 
removed from arterial wall macrophages and routed to the liver for disposal, is widely 
considered the main mechanism responsible for HDL-mediated atheroprotection [Cuchel 
2006]. The efflux of unesterified cholesterol from peripheral cells to extracellular acceptors is 
the first and rate-limiting step of RCT. This movement can occur simply by aqueous diffusion, 
or through three pathways involving distinct cell membrane proteins [Jessup 2006]: 
(i) an ATP-dependent pathway mediated by the ATP binding cassette A1 (ABCA1) transporter; 
(ii) an ATP-dependent pathway mediated by the ABCG1 transporter; 
(iii) an ATP-independent pathway involving the scavenger receptor type BI (SR-BI). 
ApoA-1 interacts with ABCA1, acquiring cellular phospholipids and cholesterol, and thereby 
forming preβ-HDL [Yokoyama 2006], which can remove further cell cholesterol via ABCA1 
[Favari 2004]. In the circulation, preβ-HDL are acted on by lecithin:cholesterol 
acyltransferase (LCAT), which esterifies cholesterol and generates α-HDL particles, the 
preferential cell cholesteroil acceptors through the ABCG1- and SR-BI-mediated pathways 
[Jessup 2006]. 
The LCAT-synthesized cholesteryl esters are transported to the liver through two major routes: 
(i) transfer by the cholesteryl ester transfer protein (CETP) to triglyceride-rich lipoproteins, 
which are metabolized into remnants and then removed by the liver, and (ii) direct uptake by 
the liver through SR-BI. In addition to the two routes for HDL-cholesteryl esters transport, 
there is also an SR-BI-dependent pathway for the direct uptake of HDL unesterified cholesterol 
in the liver [Cuchel 2006]. Beside their major function in RCT, HDL exert a series of non-lipid 
related atheroprotective activities, such as maintaining of endothelial cell homeostasis 
[Calabresi 2003].  
HDL have become a major target for the development of novel therapies for the treatment of 
atherosclerotic cardiovascular disease [Linsel-Nitschke 2005]. However, doubts on the 
clinical benefit achievable with such interventions have been raised by the failure of 
torcetrapib (Barter 2007b), a small lipophilic molecule that binds CETP. The failure of 
torcetrapib, however, does not mean that the concept of targeting HDL to further reduce 
cardiovascular risk is definitely dead. Indeed, other CETP inhibitors lacking aldosterone and 
blood pressure effects are at advances stages of clinical development [Rennings	  2008; 
Bloomfield 2009]. 
 
LCAT (lecithin:cholesterol acyltransferase) catalyzes the transacylation of the sn-2 fatty acid 
of lecithin to the free 3-OH group of cholesterol, generating cholesteryl ester (CE) and 
lysolecithin [Jonas 2000]. By this way, the LCAT reaction accounts for the synthesis of most of 
the plasma CE. The preferred lipoprotein substrate for LCAT is a newly assembled small, 
discoidal HDL migrating in preβ position on agarose gel, thus called preβ-­‐HDL [Nakamura 
2004]. The formation and accumulation of CE within these particles leads to conversion into 
spherical, α-migrating HDL, which comprise most of the plasma HDL. preβ-­‐HDL have a short 
plasma half-life, being rapidly cleared through the kidney [Rye 2004], white mature α-HDL 
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have a much slower turnover. LCAT thus plays a central role in intravascular HDL 
metabolism and in the determination of plasma HDL levels. 
In addition to its function in HDL metabolism, LCAT has also long been believed to play a 
critical role in macrophage RCT. However, the most recent findings have questioned the 
critical role of LCAT in RCT. Human LCAT overexpression in mice remarkably increases 
plasma HDL levels but does not enhance macrophage RCT in vivo. Conversely, LCAT-
deficient mice display an almost preserved macrophage RCT in vivo despite a severe plasma 
HDL reduction [Tanigawa 2009]. These mouse findings are consistent with early data in 
humans, showing that sera form carriers of genetic LCAT deficiency can efficiently remove 
cholesterol from macrophages [Calabresi 2009b] and that HDL are capable of directly 
delivering large amounts of unesterified cholesterol to the liver via SR-BI, without LCAT-
mediated conversion into CE [Schwartz 1982; Schwartz 2004].  
The effect of LCAT on atherogenesis is still controversial. Studies in animals overexpressing or 
lacking LCAT have provided inconsistent results. LCAT overexpression in mice or rabbits 
remarkably increases plasma HDL levels, and is associated with protection against diet-
induced atherosclerosis in rabbits but not in mice. Mice lacking the LCAT gene show the 
expected reductions in plasma HDL levels and have less or more atherosclerosis than their 
counterparts with active LCAT, mostly depending on the plasma levels of apoB-containing 
lipoproteins [Rousset 2009]. Early cross-sectional studies in humans have reported either 
decreased [Solajić-Bozicević1991; Solajić-Bozicević 1994]; or increased [Wells 1986] LCAT 
activity in patients with angiographically proven coronary artery disease.  
A recent study evaluated carotid atherosclerosis in Italian carriers of genetic LCAT deficiency, 
showing that the inheritance of a mutated LCAT genotype has a remarkable gene-dose-
dependent effect in reducing carotid IMT [Calabresi 2009a]. These surprising results suggest 
that the presence of defective LCAT may not preclude cholesterol removal from the arterial 
wall, and efficient reverse cholesterol transport. Indeed, sera from the same carriers of LCAT 
gene mutations displayed an enhanced capacity for ABCA1-mediated cell cholesterol efflux 
than sera from non affected family members, due to the greater content of preβ-­‐HDL particles 
[Calabresi 2009b]. Recently, the first prospective study relating LCAT concentration to future 
cardiovascular events showed that low LCAT plasma levels are not associated with increased 
atherosclerosis in the general population. Interestingly, a gender-specific analysis showed that 
higher LCAT levels in women are associated with an increased cardiovascular risk 
[Holleboom 2010]. More recently, Baldassarre and colleagues measured plasma LCAT 
concentration in European individuals associated with a high cardiovascular risk [Baldassarre 
2010], to look at the relation between LCAT and atherosclerosis, and their results were similar 
to those of Calabresi and colleagues [Calabresi 2011].  
These recent data, together with findings about genetic LCAT deficiency, challenge the idea 
that LCAT is atheroprotective and suggest that, despite positive effects on plasma HDL 
concentration, elevating LCAT expression and/or activity is not a promising therapeutic 
strategy to reduce cardiovascular risk. On the contrary, decreasing LCAT activity has 
certainly negative effects on plasma HDL concentration but possibly positive effects on HDL 
structure/function, and may represent a new therapeutic strategy to reduce cardiovascular 
risk. This option has never been tested before, and it represents the basis of this thesis.  
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1.1	  	   BIOLOGICAL	  INTRODUCTION	  
 
Atherosclerosis 
The term arteriosclerosis denotes a thickening of artery walls. Atherosclerosis, a particular kind 
of arteriosclerosis, concerns exclusively the large vessels [Ross 1986]. The disease has its own 
evolution, but it is also the cause of such acute cardiovascular events as myocardial infarction, 
stroke and peripheral vascular disease [Ross 1993]. Atherosclerosis is induced by an imbalance 
between noxious stimuli, such as dyslipoproteinemia or hypercholesterolemia, and the healing 
responses of the artery wall [DePalma 1978]. 
Complications of atherosclerosis still account for half of the deaths in the industrialized 
societies. In addition, the quality of life of millions of people is adversely affected by angina 
and heart failure caused by coronary artery disease (CAD), by intermittent claudication 
secondary to peripheral vascular disease, and by transient ischemic episodes secondary to 
cerebrovascular disease. It is for these reasons that so much attention is directed toward 
understanding the etiology of hyperlipidemia and developing effective therapeutic strategies. 
Our current knowledge is based on a large number of animal studies and on many large, 
randomized, double-blind studies in human beings that prove beyond doubt the cause-and-
effect relationship between hypercholesterolemia and morbidity/mortality from CAD, 
particularly for individuals with multiple risk factors and/or with existing CAD [Brown 1993; 
Superko 1994; Tyroler 1987]. A control of hyperlipidemia for such individuals is highly 
effective in reducing risk as demonstrated dramatically in the Scandinavia 4S study, which 
showed that cholesterol reduction not only decreased CAD mortality by 42% over a 6-years 
period, but also led to a 30% reduction in overall mortality. There was also a 30% reduction in 
cerebrovascular events [Scandinavian Simvastatin Survival Study 1994]. 
 
Cholesterol metabolism 
A primary risk factor predisposing to heart disease is an abnormally elevated level of 
cholesterol in the blood; cholesterol accumulation in the blood is correlated with development 
of atherosclerotic plaques. 
Cholesterol is only slightly soluble in water, but it is insoluble in blood, and for this reason it is 
transported in the circulatory system as component of large macromolecular complexes, termed 
lipoproteins. These lipid::protein complexes are particles with an exterior composed of 
amphiphilic proteins and lipids whose outward-facing surfaces are water-soluble and inward-
facing surfaces are lipid-soluble, allowing movement of apolar lipids through aqueous 
environments. A total of nine major apolipoproteins are found in human lipoproteins 
[Mackness 1992]. The standard lipoproteins are classified according to their increasing density: 
chylomicrons, very-low-density lipoprotein (VLDL), intermediate-density lipoprotein (IDL), 
low-density lipoprotein (LDL), and high-density lipoprotein (HDL). Because lipids are of 
much lower density than proteins, the lipid content of a lipoprotein class is inversely related to 
its density. 
In addition to transporting cholesterol through the blood, lipoproteins have cell-targeting 
signals that direct the lipids they carry to specific tissues. 
Despite their differences in lipid and protein composition, all lipoproteins share common 
structural features, notably a spherical shape that can be detected by electron microscopy 
(Figure 1.1). 
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Figure 1.1.  Lipoprotein scheme and electron microscopic analysis of lipoprotein fractions [from 
http://www.utpa.edu/faculty/ahmad/Adv-Biochem/Lipid%20biosynthesis-3_files/frame.htm] 
 
Chylomicrons represent the form through which dietary fat is transported from intestine to 
peripheral tissue, notably heart, muscle, and adipose tissue. VLDL molecules play a 
comparable role for triacylglycerols synthesized in liver. The triacylglycerols in both 
lipoproteins are hydrolysed to glycerol and fatty acids at the inner surfaces of capillaries in the 
peripheral tissues. This hydrolysis involves activation of extracellular enzyme lipoprotein 
lipase by apoliprotein C-II. 
VLDL are produced by the liver and contain apolipoprotein B100 and apolipoprotein E in their 
shells. During transport in the bloodstream, the blood vessels cleave and absorb more 
triacylglycerol from IDL molecules, which contain an even higher percentage of cholesterol. 
The IDL molecules have two possible fates: half enter metabolism by hepatic lipases, taken up 
by the LDL receptor on the liver cell surfaces, and the other half continue to lose 
triacylglycerols in the bloodstream until they form LDL molecules, which contain the highest 
percentage of cholesterol. 
LDL is the principal form through which cholesterol is transported to tissues; each molecule 
contains approximately 1500 molecules of cholesterol ester. 
Each LDL particle contains one molecule of apolipoprotein B100, which is recognized by the 
LDL receptor in peripheral tissues. Upon binding of apolipoprotein B100, many LDL receptors 
become localized in clathrin-coated pits. Both the LDL and its receptor are internalized by 
endocytosis to form a vesicle within the cell. The vesicle then fuses with a lysosome, which has 
an enzyme called lysosomal acid lipase that hydrolyses the cholesterol esters. Now within the 
cell, the cholesterol can be used for membrane biosynthesis or esterified and stored within the 
cell, so as to not interfere with cell membranes. Synthesis of the LDL receptor is regulated by 
SREBP, the same regulatory protein as is used to control synthesis of cholesterol de novo in 
response to cholesterol presence in the cell. When the cell has abundant cholesterol, LDL 
receptor synthesis is blocked so new cholesterol in the form of LDL molecules cannot be taken 
up. On the converse, more LDL receptors are made when the cell is deficient in cholesterol. 
When this system is deregulated, many LDL molecules appear in the blood without receptors 
on the peripheral tissues. These LDL molecules are oxidized and taken up by macrophages, 
which become engorged and form foam cells. These cells often become trapped in the walls of 
blood vessels and contribute to atherosclerotic plaque formation. Differences in cholesterol 
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homeostasis affect the development of early atherosclerosis (carotid intima-media thickness). 
These plaques are the main causes of heart attacks, strokes, and other serious medical 
problems, leading to the association of so-called LDL cholesterol (actually a lipoprotein) with 
"bad" cholesterol. 
HDL play the primary role in returning excess cholesterol from tissues to the liver for 
metabolism or excretion, in a process known as reverse cholesterol transport (RCT). Having 
large numbers of large HDL particles correlates with better health outcomes. In contrast, 
having small numbers of large HDL particles is independently associated with atheromatous 
disease progression within the arteries: for this reason, cholesterol in HDL is called “good” 
[Montgomery 1990; Franceschini 1991]. 
Cholesterol in plasma lipoproteins exists both as free sterol and as cholesterol esters. 
Cholesterol esters are considerably more hydrophobic than cholesterol itself. Cholesterol 
esterification has been described for the first time in 1935 by Sperry [Sperry 1935], but he 
attributed esters production to plasma heating to 55-60°C. In 1962, Glomset [Glomset 1962] 
identified an enzyme responsible for cholesterol ester synthesis in plasma: Lecithin:cholesterol 
acyltransferase (LCAT) (EC2.3.1.43), also known as Phosphatidylcholine-sterol 
acyltransferase. During the following years, Glomset described the key role of LCAT in the 
RCT pathway, the process in which excess cholesterol is removed from macrophages in arterial 
walls by HDL and delivered to the liver for biliary excretion. 
After discovery of the LCAT role in cholesterol metabolism, and in the formation and 
maturation of HDL, interest in the enzyme increased. Currently, numerous animal models 
lacking or overexpressing LCAT, including mice, hamsters, rabbits and monkeys, have been 
generated to investigate the role of LCAT in lipoprotein metabolism, in RCT and in 
atherosclerosis, and over 60 different mutations in LCAT gene have been described. 
 
LCAT Biochemistry 
The human Lcat gene is a 4.5 kb gene localized at the q21-22 region of chromosome 16; it is 
composed of 6 exons separated by 5 introns, containing 1.5 kb of coding sequence [Jonas 
2000]. It was sequenced and cloned for the first time in 1986 by McLean et al. [McLean 1986]. 
Lcat gene is mainly expressed in the liver but the enzyme is also produced in testes and by 
astrocytes in brain, where it catalyzes the cholesterol esterification in nascent apoE-containing 
lipoproteins secreted from glia. 
The synthesized protein is secreted into plasma and in cerebral spinal fluid. The plasma 
concentration of LCAT is about 6 µg/ml and varies in adults with age, gender, alimentary 
habits and smoking. The half-life of human LCAT in plasma is estimated in 4-5 days. 
The mature LCAT contains 416 amino acids, with a molecular mass of approx. 63 kDa, which 
is more than 20% greater than the predicted protein mass. The extra mass is due to different 
post-translational modifications: two O-glycosylations on Thr407 and Ser409 consisting of 
sialylated galactose β, and four N-glycosylations (Asn20, Asn84, Asn272 and Asn384) 
containing sialylated triantennary and/or biantennary complexes. The carbohydrate content is 
about 25% of its total mass, with the majority being N-linked. Removal of the carbohydrate 
moieties from isolated human LCAT by neuraminidase is associated with a 60% increase in the 
enzymatic activity [Doi 1983], but inhibition of glycosylation in CHO cells reduces the 
enzymatic activity without affecting LCAT protein secretion [Collet 1991]. Different site-
directed mutagenesis studies have been performed to investigate the post-translational 
modifications. Qu and colleagues [Qu 1993] in transfected COS-6 cells mutated Asn into Thr; 
they showed that Asn272 is essential for secretion of active LCAT, while Asn84 is critical for 
its full activity, but not for intracellular processing. In another study in COS-1 cells, Karmin 
and colleagues [Karmin 1993] substituted Asn with Gln, showing that glycosylation at all four 
sites is required to generate the full-size mature LCAT protein, but deletion of only one of the 
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N-linked glycosylation sites does not affect intracellular processing and secretion. N-linked 
glycosylations are connected with the catalytic activity of the enzyme: substitution of Asn84 or 
Asn272 with Gln leads to a 82% and 62% decrease in activity, while replacement of Asn384 
leads to a substantially increased activity. The pattern of N-linked glycosylation, however, has 
profound effects on the catalytic activity of the enzyme. Substitutions of Asn84 and Asn272 
with Gln result in a loss of activity respectively of 82% and 62%, while replacement of Asn384 
leads to a substantially increased activity. Furthermore, N-glycosylation seems to be important 
for determining substrate specificity towards native HDL and LDL. 
The biological significance of the two O-glycosylation sites has not been clarified. 
 
LCAT is responsible for the conversion of free cholesterol into cholesteryl esters. The catalysis 
is greatly stimulated by the major HDL apolipoprotein, apoA-I, and to a lesser extent by apoC-
I, apoE, and apoA-IV. 
The LCAT reaction consists in a transesterification, in which a fatty acid at the sn-2 position of 
phosphatidylcholine, or lecithin, is transferred to the free hydroxyl group of cholesterol, and in 
the meantime phosphatidylcholine is converted into lysophosphatidylcholines. This occurs in 
two steps. After binding to a lipoprotein, LCAT cleaves the fatty acid in sn-2 position of 
phosphatidylcholine and transfers it onto Ser181. This step is mediated by the phospholipase 
activity of LCAT and depends on the phosphatidylcholine composition. Next, the fatty acid is 
transesterified to the 3-β-hydroxyl group on the A-ring of cholesterol to form cholesteryl ester 
(Figure 1.2). Finally, the cholesteryl esters produced, more hydrophobic than free cholesterol, 
migrate into the hydrophobic core of HDL. However, at an atomic level, the mechanism is not 
yet well described. 
However, at an atomic level, the mechanism is not yet well described. 
This reaction would proceed by a chemical mechanism similar to that proposed by Kinnunen et 
al. for lipoprotein lipase [Kinnunen 1982] and shared by serine-histidine esterases [Brady 
1990; Nemukhin 2006]. 
 
 
 
Figure 1.2. Summary of LCAT role: theoretical enzymatic mechanism [from Peter 2007]. 
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In nature, the aptitude to convert esters, amides and peptides has evolved independently on 
several distinct occasions. The most common structural theme is enzymes with a serine-
histidine-aspartate/glutamate triad. So far, similar triads were observed in many proteins, 
comprising proteases, esterases and lipases and, in some cases, Asp was replaced with Glu. 
LCAT shares with these enzymes the catalytic triad, consisting of Ser 181, His 244 and  
Asp 275. 
The triad catalytic mechanism involves nucleophilic attack on the carboxyl carbon by Ser Oγ. 
For transferring the Ser hydroxyl proton to the leaving group, nucleophilicity is enhanced 
through acid/base catalysis by His, forming an acylenzyme. In the deacylation reaction, His 
assists the nucleophilic attack on the acylenzyme ester by an acyl acceptor (e.g. water or an 
amine and, in LCAT, cholesterol) by transferring its proton to Ser Oγ. In the reaction, a 
tetrahedral intermediate is expected. The activation energy barrier for the reaction is lowered 
by stabilizing interactions between the transition state and the enzyme, notably between the 
transition state and features of the enzyme forming an "oxyanion hole". 
Ser has a crucial role in the catalytic mechanism and is the core residue of the active site. Its Oγ 
has to be accessible from both the inside and the outside of the protein. This requires the 
absence of bulky obstructing side chains. For this reason, in its immediate vicinity in the 
sequence, glycine residues are often observed [Rawlings 1994], such as in α/β hydrolase family 
members; for instance, in LCAT, we can recognize a GHSGL pattern. 
His role is as crucial as that of Ser. Its sequence position is variable, but in three-dimensional 
space it is almost invariably close to Ser with its Nε2, while forming a hydrogen bond to the 
carboxylate with its Nδ1 (2.6-3.0 Å in trypsin crystal structures, 2.9 Å in inhibited elastase). 
The role of Asp, which is invariably strongly hydrogen-bonded to Nδ1 of His, is to polarize the 
system and make Ser unusually reactive. In detail, it is important for the stabilization of the 
positively charged protonated His, stabilizing its correct tautomer and conformation. 
 
Human LCAT preferentially acts on phospholipids containing 18:1 or 18:2 fatty acids, whereas 
rat and mouse LCAT prefer phospholipids containing 20:4 fatty acids [Grove 1991]. Other 
phospholipids, such as phosphatidylethanolamine, can also participate in the LCAT reaction, 
whereas other lipids, such as sphingomyelin, can inhibit LCAT [Bolin 1996; Sparks 1989]. 
Approximately 75% of plasma LCAT activity is associated with cholesterol on HDL, the 
referred natural substrate, but LCAT is also able to bind and produce cholesteryl esters on LDL 
and other apoB-containing lipoproteins. The LCAT activity is thus distinct in α -activity, if 
LCAT acts on cholesterol bound to apoA-I-containing lipoproteins (HDL particles), and β-
activity, if LCAT works on cholesterol bound to apoB-containing lipoproteins (VLDL and 
LDL particles). 
Among other defined structural elements in LCAT are two sets of disulfide bridges, Cys50–
Cys74 and Cys313–Cys356. The Cys50–Cys74 disulfide was reported to be essential for the 
binding of LCAT to lipoprotein surfaces [Baldassarre 2010] and appears to be located in the 
putative ‘lid’ region that may cover the active site [Calabresi 2011]. Peelman [Peelman 1998] 
reported that deletion of amino acids at positions 56 to 68 gave a mutant LCAT that was not 
active on any substrate. 
 
In different studies [Kosek 1999], some kinetic parameters of LCAT α-activity were collected. 
The equilibrium dissociation constants (Kd) for the interaction of pure human LCAT with 
LDL, HDL2, HDL3, and reconstituted discoidal HDL (rHDL) are as follows: rHDL = HDL3 
</= HDL2 < LDL, with Km=0.10 mM for HDL3, Km=0.4 mM for HDL2 and Km=0.97 mM 
for LDL and with relative reactivities (app Vmax/app Km) of 100, 16, 1.3 and 6.5%, 
respectively. 
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LCAT in HDL metabolism 
LCAT plays a central role in intravascular HDL metabolism and in the determination of plasma 
HDL levels (Figure 1.3). The LCAT preferred lipoprotein substrate is a newly assembled 
small, discoidal-shaped HDL generated through the interaction of lipid-free or lipid-poor 
apolipoprotein A-I with the adenosine triphosphate-binding cassette transporter A1 (ABCA1) 
located on the plasma membrane, in liver or intestine. These nascent discoidal HDL are called 
preβ HDL. 
Upon its association with the preβ HDL particle, cholesterol is esterified by LCAT and 
migrates into the hydrophobic core of the lipoprotein, converting the particles into mature, 
spherical-shaped, and α-migrating HDL (α-HDL) [Nakamura 2004]. 
Importantly, upon esterification of cholesterol in HDL, LCAT maintains the gradient of free 
cholesterol between the cellular membrane and the surface of the HDL particle, which is 
thought to generate a continuous flow of cholesterol from the cell to lipoproteins and prevent 
the transfer of cholesterol back to the cell. 
α-HDL can be converted back to preβ-HDL through the concerted action of the cholesteryl 
ester transfer protein (CETP) and of a variety of lipases. Preβ HDL have a short plasma half-
life, being rapidly cleared through the kidney, whereas mature α -HDL have a much slower 
turnover [Rye 2004]. 
 
 
 
Figure 1.3. Pathways influencing HDL cholesterol metabolism and flux and potential relationship with atherosclerosis 
[from Rader 2012]. 
 
In addition to its function in HDL metabolism, LCAT has also long been believed to play a 
crucial and critical role in macrophage reverse cholesterol transport (RCT). Through this 
process, HDL remove excess cholesterol from macrophages within the arterial wall and 
subsequently deliver it to the liver for biliary excretion - a function that may well explain HDL-
mediated atheroprotection. In their paper, Glomset and colleagues [Glomset 1962; John 1970] 
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described how LCAT activity could contribute to cell cholesterol egress, assuming that “LCAT 
normally reduces this excess lipid through a combination of direct and indirect effects”. 
The effect of LCAT on the flux of cholesterol may depend both on the type and metabolic 
status of the cells, and on the environment of HDL in the extracellular medium. 
 
LCAT in animal models 
For several reasons, LCAT role in RCT, and particularly as an atheroprotective factor, is under 
debate. To better investigate this feature, several experimental systems were developed in 
various animal models, but they provided inconsistent results. 
Human LCAT overexpression in mice remarkably increases plasma HDL levels, but does not 
enhance macrophage RCT in vivo and LCAT-deficient mice display a largely preserved 
macrophage RCT despite a severe plasma HDL reduction, mostly due to high plasma content 
of preβ-HDL and enhanced macrophage cholesterol removal via ABCA1 [Tanigawa 2009]. 
These mouse findings are consistent with early data in humans, showing that HDL are capable 
of directly delivering large amounts of free cholesterol to the liver, without LCAT-mediated 
conversion into cholesteryl esters [Calabresi 2009b]. LCAT has also been overexpressed in 
transgenic rabbits [Hoeg 1996], which - differently from mice - express CETP [Rousset 2009]. 
As observed in mice, overexpression of LCAT in rabbits also increases HDL but, differently 
from mice, it decreases LDL and reduces atherosclerosis with respect to control animals. 
Notably, the double transgenic mice expressing both LCAT and CETP develop less 
atherosclerosis than LCAT transgenic mice, although more than wild-type mice. 
Transient expression of human LCAT in squirrel monkeys with adenovirus also raises HDL 
and decreases apoB-lipoproteins, due to increased catabolism [Amar 2009]. 
Studies of mice lacking LCAT gene (LCAT KO mice) have also advanced our knowledge of 
the role of LCAT on HDL metabolism. LCAT KO mice have markedly reduced plasma total 
cholesterol, cholesteryl esters, HDL, apoA-I, and an increase in plasma triglycerides. The 
amount of α-HDL is strikingly decreased and the residual HDL is mostly preβ-HDL [Rousset 
2009]. 
Unexpectedly, LCAT deficiency in mice significantly reduces diet-induced atherosclerosis 
when on a high cholesterol diet, despite causing a marked decrease of HDL [Lambert 2001]. In 
this case, LCAT deficiency is associated with a significant decrease of apoB-containing 
lipoproteins. 
LCAT also transesterifies and hydrolyzes platelet activating factor and oxidized phospholipids 
with long chains in the sn-2 position. Thus, LCAT is expected to contribute to the antioxidant 
or anti-inflammatory properties of HDL. 
LCAT deficiency in mice is associated with enhanced insulin sensitivity. Furthermore, it was 
recently reported that LCAT-deficient mice, especially females, are protected against high-fat, 
high-sucrose (HFHS) diet-induced obesity. These protective metabolic phenotypes are 
associated with protection against diet-induced hepatic and adipocyte ER stress, but the 
mechanistic link with the enzymatic action of LCAT needs further investigation [Li 2011]. 
Therefore, in addition to its role in RCT, LCAT directly or indirectly interferes with several 
other physiological processes that might affect the development of atherosclerosis. Overall, the 
results from the various animal models indicate that there is a complex interaction between 
LCAT and atherosclerosis, which depends on the diet. It appears, however, that the anti-
atherogenic effect of LCAT more closely correlates with its ability to lower plasma levels of 
apoB-containing lipoproteins than on its ability to raise HDL. 
 
Human genetic disorders of LCAT 
Over 60 different mutations in the human LCAT gene have been described [Kuivenhoven 
1997] (mutations are collected in http://www.lcat.it/database.html), which cause two rare 
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LCAT deficiency syndromes, namely familial LCAT deficiency [Gjone 1968], FLD (MIM n. 
245900) and fish-eye disease [Carlson 1979], FED (MIM n. 136120).  
LCAT deficiency is a rare disorder. In general, the prevalence of LCAT mutations in subjects 
with low HDL cholesterol has been estimated at 2–16% in Finnish and Caucasian Canadian 
patients, respectively. In the recently published results of the Copenhagen City Heart Study in 
which the regulatory and coding regions of LCAT were re-sequenced in individuals with the 
2% lowest (n=180) plasma HDL cholesterol levels, no carriers of loss-of-function mutations in 
LCAT were identified, indicating that these are extremely rare in the general population. In the 
Netherlands, however, functional mutations in LCAT were found in almost a third (29%) of 
patients with low HDL cholesterol, thus constituting a common cause of low HDL cholesterol 
in referred patients in this country. Interestingly, a recent genome-wide association study 
(GWAS) in more than 100,000 individuals of European ancestry identified a single-nucleotide 
polymorphism (SNP) in LCAT as the strongest marker of isolated variation in HDL cholesterol 
levels [Haase 2010]. 
FLD was reported for the first time in 1967 in a Norwegian family [Norum 1967]. In this 
family, three adult sisters showed extremely low plasma LCAT activity, reduced levels of 
cholesteryl esters, and reduced plasma LCAT concentration. Years later it was established that 
homozygosis for a single nucleotide substitution in codon 252 of exon 6 in the gene, leading to 
the exchange of a methionine (ATG) for a lysine residue (AAG), was responsible for the 
LCAT deficiency in this family. 
In FLD mutants, LCAT production is abolished or the synthetized enzyme lacks both α-LCAT 
and β -LCAT activity; instead, in FED mutants, α -LCAT activity is missing, but β -LCAT 
activity is preserved. Some LCAT mutations have been shown to selectively affect LCAT 
activity on HDL, but not all mutations can be neatly categorized as affecting only the 
esterification of cholesterol on HDL or LDL, suggesting that some patients with FED may 
differ from FLD by having more residual LCAT activity on both HDL and LDL [Klein 1995]. 
Both conditions are characterized by low HDL and corneal opacities, but FLD subjects have a 
more severe deficiency of LCAT and can develop other signs and symptoms. In detail, 
homozygous FLD cases have very little cholesteryl esters in plasma and unesterified 
cholesterol accumulates in all plasma lipoprotein fractions; in addition to the corneal opacity, 
they reportedly present anemia, and many of them unpredictably develop renal disease. The 
FED cases have subnormal plasma cholesteryl ester/unesterified cholesterol ratios and a milder 
clinical phenotype. Heterozygous carriers have an intermediate lipid/lipoprotein phenotype, 
with a significant LCAT gene-dose-dependent effect on plasma cholesterol esterification, lipid, 
and apolipoprotein levels [Carlson 1985]. 
However, the differential diagnosis cannot be defined a priori; to discriminate FLD and FED 
pathology in carriers of two mutant LCAT alleles, it is mandatory to measure the ability of 
plasma to esterify cholesterol incorporated into endogenous lipoproteins (α-LCAT and β -
LCAT activity) and into a standard HDL substrate (α-LCAT). 
In 1997, Kuivenhoven et al. proposed a new classification system for natural LCAT mutations 
based on the different biochemical and clinical phenotypes observed in LCAT-deficient 
patients as well as on the biochemical characteristics of mammalian cell cultures expressing the 
mutants of the LCAT gene [Kuivenhoven 1997]. Importantly, this new system also allows the 
classification of heterozygous mutations. Intermediate phenotypes, i.e. due to mutations not 
causing a total loss of LCAT activity (FLD), but causing more than “just” partial loss of LCAT 
activity against HDL (FED) are also taken into account. For the in vivo classification, five 
criteria were proposed: 1) LCAT activity towards HDL analogues; 2) cholesterol esterification 
rate (endogenous lipoproteins); 3) ratio of plasma FC to EC; 4) plasma LCAT concentration; 5) 
clinical symptoms of the disease. For the in vitro experiments, two criteria were proposed: 1) 
specific activity of the mutant protein towards HDL analogues and native LDL, and 2) activity 
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of the mutant protein towards heat-inactivated plasma. The classification system describes five 
classes. The first class contains null mutations of the LCAT gene. This means that patients in 
this class display a total loss of catalytic activity of LCAT and that they have the clinical 
phenotype of FLD. The second class contains missense mutations that cause complete or nearly 
complete loss of catalytic activity of the LCAT gene. The third class contains both missense 
mutations and minor deletions in the LCAT gene that are responsible for an intermediate 
phenotype, meaning that there is either partial loss of activity against LDL or combined partial 
loss of activity against both HDL and LDL. This class thus also includes patients that show 
FED symptoms, but do not develop all the symptoms of the FLD syndrome. The fourth class 
contains the mutations responsible for the typical symptoms of the FED syndrome. This class 
thus includes missense mutations that result in specific loss of activity against HDL analogues, 
but activity against LDL or other apoB-containing lipoproteins is preserved. The fifth and last 
class contains three mutations that the group of Kuivenhoven et al. was unable to categorize; 
this category was therefore named “unclassified mutations”. 
 
LCAT and atherosclerosis 
As LCAT was considered the main driving force in the reverse cholesterol transport pathway, 
it was soon thought that the enzymatic activity of LCAT could be involved in the protection 
against atherosclerotic lesion formation [Rousset 2009; Calabresi 2010]. In 1973, Hovig and 
Gjone demonstrated lipid deposition in renal arteries and veins of patients with FLD [Hovig 
1973]. Furthermore, the spleen contains numerous lipid-laden cells, which are assumed to be 
partly responsible for the splenomegaly found in FLD patients. Notably, only 35% of the total 
cholesterol is esterified in arterial lipid depositions of FLD patients, as compared to 75 % in 
normal atheromas. In 1982, Carlson showed that FED patients did not suffer from premature 
atherosclerosis in spite of their extremely low HDL cholesterol levels [Carlson 1982]. This was 
surprising, as FED patients have very low levels of HDL and it thus was expected that these 
patients would have an increased risk for atherosclerosis. 
Ever since then, the effect of LCAT on human atherogenesis has been controversial. Early 
cross-sectional studies have reported either decreased or increased LCAT activity in patients 
with angiographically proven CAD; moreover, an enhanced cholesterol esterification rate was 
shown to be a strong predictor of the presence of angiographically proven atherosclerotic 
lesions. 
Recently, a relatively large study on carriers of LCAT defects has reported not only reduced 
HDL but also a marked increase in C-reactive protein and in intima/media thickness (IMT) of 
the artery [Calabresi 2009a]. No significant change in IMT was observed in homozygotes, but 
an increased incidence of CHD was reported when heterozygotes were compared with controls. 
Similar findings for heterozygous subjects were observed in a 25 years follow-up study of a 
large Canadian LCAT-deficient family and in 13 unrelated Italian families with FLD and FED. 
These results suggest that, while heterozygosis for LCAT deficiency is associated with 
increased IMT and CHD, this may not be true for homozygous subjects; however, this puzzling 
result could potentially be explained by the low number of homozygous subjects studied. An 
alternative explanation is that homozygous FLD and FED patients may be partially protected 
from their low HDL, because they often also have reduced levels of LDL compared to 
heterozygotes and controls. 
LCAT is not an extensively polymorphic protein and only a few studies examining genetic 
variants of the LCAT gene in the general population have been carried out. 
Recently, a study reported greater IMT and elevated LCAT activity in subjects with metabolic 
syndrome, suggesting that higher LCAT activity may not be beneficial [Dullaart 2008]. A 
similar positive association of LCAT was also observed in patients with angiographically 
proven CHD [Wells 1986]. These results are in contrast, however, with several earlier papers 
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describing either a negative correlation or no association between LCAT activity and CHD. 
These seemingly contradictory results may potentially be explained by the fact that most of 
these studies are relatively small and do not examine the other proteins and enzymes in the 
RCT pathway, which can potentially alter the effect of LCAT on atherosclerosis. For example, 
low LCAT activity when also linked with elevated levels of pre-beta HDL was associated CHD 
[Miida 1996; Savel 2012]. Another possible explanation for these contradictory results is that 
there may be other biochemical markers, such as the fractional esterification rate of apoB-
depleted plasma (FERHDL), that are better than the in vitro LCAT activity assay for assessing 
the HDL maturation process [Frohlich 2003]. Finally, it is important to note that it is 
impossible to determine from epidemiologic studies whether LCAT is playing a causal role in 
promoting or decreasing atherosclerosis or instead may be up or down regulated by some sort 
of compensatory response. 
 
Therapeutic regulation of LCAT 
Therapeutic up-regulation of LCAT function has gained interest in the recent years, not only as 
enzyme replacement therapy for LCAT deficiency syndromes, but also as a potential new 
therapeutic strategy for reducing atherosclerosis. Strategies for therapeutically raising LCAT 
activity include recombinant LCAT protein administration, viral expression of LCAT, and 
small molecule activators of LCAT. 
Intravenous infusion of recombinant LCAT in LCAT knockout mice with or without 
expression of human apoA-I rapidly raises HDL cholesterol and relieves other lipid 
abnormalities. Moreover, a preliminary report indicates that subcutaneous injection of 
recombinant LCAT stimulates reverse cholesterol transport and attenuates atherosclerosis 
progression in New Zealand White rabbits [Zhou 2009]. 
Kuroda and colleagues have focused on developing a long-lasting LCAT replacement therapy 
via transplantation of human LCAT gene-transduced autologous adipocytes [Kuroda 2012]. 
LCAT from the transduced adipocytes improves the abnormal HDL particles from a FED 
patient in vitro. Furthermore, LCAT can be steadily detected in adipocyte-transplanted mice 
four weeks after transplantation. Lastly, the therapeutic potential of a small molecule activator 
of LCAT, compound A, is being explored for the treatment of atherosclerosis. Compound A 
increases LCAT activity at a micromolar concentration, by interacting with the free sulfhydryl 
group in Cys31 near the catalytic site of LCAT. Cys 31 is a conserved residue in multiple 
species and, on purely theoretical grounds, compound A is able to activate LCAT from 
multiple species, including mouse, hamster, rhesus monkey, and man. Intraperitoneal 
administration of 20 mg/kg of compound A increases HDL cholesterol acutely in C57Bl/6 
mice and in high-fat diet fed Syrian golden hamsters, while non-HDL cholesterol and 
triglycerides are reduced [Chen 2012]. Also chronic daily administration of 20 mg/kg and 60 
mg/kg via oral gavage into high-fat diet fed Syrian golden hamsters leads to a dose-dependent 
increase in HDL cholesterol. VLDL cholesterol is decreased at the dose of 20 mg/kg, but no 
further decrease is seen after administration of 60 mg/kg. Gall bladder bile acids at termination 
are increased 2-fold, indicative of enhanced RCT upon chronic treatment with the LCAT 
activating compound A. The effects of these studies with respect to the generation of a more 
anti-atherogenic lipoprotein profile look promising. 
 
Another interesting strategy for atherosclerosis therapy has been focused on CETP modulation: 
many studies suggested that CETP inhibition could exert a cardio-protective effect, specifically 
stimulating cell efflux [Barter 2007a; Calabresi 2009b; Niesor 2010]. Zhen and colleagues 
recently applied the adeno-associated viral vector serotype 8 (AAV8) for liver-directed 
delivery of human LCAT in heterozygous LDL receptor knockout mice expressing CETP. 
AAV8-hLCAT administration resulted in a hLCAT concentration of 300 µg/mL, which 
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declined slightly over the course of the experiment to 220 µg/mL, a level which is estimated to 
be 20-fold higher than the physiological concentration of LCAT. The mice showed a markedly 
raised HDL cholesterol and increased particle size, while LDL cholesterol, plasma 
triglycerides, and plasma apoB were reduced. 
Nicholls and colleagues [Nicholls 2011] tested the effect of CEPT inhibitors in patients with 
dyslipidemia and demonstrated that, compared with placebo or statin in monotherapy, these 
inhibitors could increase HDL-C and decrease LDL-C levels. Zanotti and colleagues obtained 
similar results using a different CETP inhibitor [Zanotti 2011]. However, this therapeutic 
strategy was found to be unsuccessful in early clinical trials, and it was discontinued due to off-
target adverse effects. 
Nevertheless, considering the complex interaction of LCAT with blood lipoproteins, extensive 
studies on the effects on atherosclerosis susceptibility should be performed in the future to be 
able to draw any sound conclusion on the therapeutic applicability of these new strategies. 
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1.2	   INFORMATICS	  INTRODUCTION	  
 
Bioinformatics 
Bioinformatics is a field of science in which biology, computer science, and information 
technology merge into a single discipline to analyse biological information using computers 
and statistical techniques. Major applications of bioinformatics include sequence alignment, 
genome assembly, protein structure prediction, protein-protein and protein-ligand docking, 
gene expression prediction, and molecular dynamics simulations. 
Molecular modeling indicates the general process of describing and studying complex 
chemical systems in terms of a realistic atomic model, with the aim to understand, predict and 
simulate macroscopic properties based on detailed knowledge at an atomic scale. The 
knowledge of the three-dimensional structure of a protein of interest is useful to plan 
experiments aimed at elucidating its function or at developing compounds that specifically 
interact with it (drug design). 
Macroscopic physical properties can be distinguished in: -­‐ static equilibrium properties, such as the binding constant of an inhibitor to an 
enzyme, the average potential energy o f a system, or the radial distribution function 
in a liquid; -­‐ dynamic or non-equilibrium properties, such as the viscosity of a liquid, diffusion 
processes in membranes, the dynamics of phase changes, reaction kinetics, or the 
dynamics of defects in crystals. 
The choice of the specific technique to be used depends on the question asked and on the 
feasibility of the method to yield reliable results at the present state of the art. Ideally, the time-
dependent Schrödinger equation describes the properties of molecular systems with high 
accuracy, but anything more complex than the equilibrium state of a few atoms cannot be 
handled at this ab initio level. Thus approximations are necessary; the higher the complexity of 
a system and the longer the time span of the processes of interest is, the more severe the 
required approximation are. At a certain point the ab initio approach must be augmented or 
replaced by empirical parameterization of the model used. Where simulations based on 
physical principles of atomic interactions still fail, due to the complexity of the systems, 
molecular modeling is based entirely on a similarity analysis of know structural and chemical 
data. The QSAR methods (Quantitative Structure-Activity Relations) and many homology-
based protein structure predictions belong to the latter category. 
Macroscopic properties are always ensemble averages over a representative statistical 
ensemble (either equilibrium or non-equilibrium) of molecular systems. For the generation of a 
representative equilibrium ensemble two methods are available: Monte Carlo simulations and 
molecular dynamics (MD) simulations. For the generation of non-equilibrium ensembles and 
for analysis of dynamic events, only the second method is appropriate. While Monte Carlo 
simulations are simpler than MD (they do not require the computations of forces), they do not 
yield significantly better statistics than MD in a given amount of computer time. Therefore MD 
is a more universal technique. If a starting configuration is very far from equilibrium, the 
forces may be excessively large and the MD simulation may fail. In those cases a robust energy 
minimization (EM) is required. Another reason to perform an energy minimization is the 
removal of kinetic energy from the systems: if several “snapshots” from a dynamical 
simulation must be compared, energy minimization reduces the thermal noise in the structures 
and potential energies, so that they can be compared better [Van der Spoel et al., 2006]. 
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Potential energy surface 
The fundamental computation at the core of a forcefield-based simulation is the calculation of 
the potential energy for a given configuration af atoms. The calculation of this energy, along 
with its first and second derivatives with respect to the atomic coordinates, yields the 
information necessary for minimization, harmonic vibrational analysis, and dynamics 
simulations. This calculation is actually performed by the simulation engine, or forcefield-
based program. Simulation engines are the computational packages that handle the application 
of forcefields in minimization, dynamics, and other molecular mechanics simulations. 
 
 
 
Figure 1.4. Schematic potential energy funnel for proteins folding (modified from Stony Brook University, 2012) 
 
The functional form of the potential energy expression and the entire set of parameters needed 
to fit the potential energy surface constitute the forcefield [Ermer, 1976]. The energy 
expression is the specific equation set up for a particular model and including (or not) any 
optional terms. For example, a forcefield would contain bond-stretching parameters for all 
combinations of atoms for which it was parameterized, as well as defined, summed functional 
forms for the bond-stretching term. The corresponding energy expression would contain bond-
stretching parameters for only those combinations of bonded atoms actually found in the model 
being studied, as well as the specific bond-stretching terms for the number and types of bonds 
in that model. 
It is important to understand that the forcefield (both the functional form and the parameters 
themselves) represents the single largest approximation in molecular modeling. The quality of 
the forcefield, its applicability to the model at hand, and its ability to predict the particular 
properties measured in the simulation directly determine the validity of the results. Molecular 
modeling programs are the graphical user interfaces that can be used to prepare models, set up 
forcefield, and access the simulation engines. 
The complete mathematical description of a molecule, including both quantum mechanical and 
relativistic effects, is a formidable problem, due to the small scale and large velocity. However 
these intricacies can be ignored, because molecular mechanics and dynamics are based on 
empirical data that implicitly incorporate all the relativistic and quantum effects. Since no 
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complete relativistic quantum mechanical theory is suitable for the description of molecular 
systems, the non-relativistic, time-dependent form of the Schrödinger description is used: 
 
 𝐻Ψ 𝑅, 𝑟 = 𝐸Ψ 𝑅, 𝑟  
    (1.1) 
where H is the Hamiltonian for the systems, Ψ   is the wavefunction, and E is the energy. In 
general, Ψ    is a function of the coordinates of the nuclei (R) and the electrons (r). Although this 
equation is quite general, it is too complex for any practical use, so approximations are made. 
Noting that the electrons are several thousands of times lighter than nuclei and therefore move 
much faster, Born and Oppenheimer proposed what is know as Born-Oppenheimer [Born & 
Oppenheimer, 1927] approximation: the motion of the electrons can be decoupled from that of 
the nuclei, giving two separate equations. The first equation describes the electronic motion: 
 𝐻ψ 𝑅; 𝑟 = 𝐸ψ 𝑟;𝑅  
    (1.2) 
and depends only parametrically on the position of the nuclei. Note that this equation defines 
an energy E(R), which is a function of only the coordinates of the nuclei. This energy is usually 
called the potential energy surface. The second equation the describes the motion of the nuclei 
on this potential energy E(R): 
 𝐻ϕ 𝑅 = 𝐸ϕ 𝑅  
    (1.3) 
The direct solution of Eq 1.2 is the solution of ab initio quantum chemical codes. 
Semiempirical codes also solve Eq. 1.2, but they approximate many of the integrals needed 
with empirically fit functions. The common feature of these programs, though, is that they 
solve for the electronic wavefunction and energy as a function of nuclear coordinates. In 
contrast, simulation engines provide an empirical fit to the potential energy surface [MSI, 
1998]. 
Solving Eq 1.3 is important if one is interested in the structure or time evolution of a model. Eq 
1.3 is the Schrödinger equation for the motion of the nuclei on the potential energy surface. In 
principle, Eq 1.2 could be solved for the potential energy E, and then Eq 1.3 could be solved. 
However, the effort required to solve Eq 1.2 is extremely large, so usually an empirical fit to 
potential energy surface, commonly called a forcefield (V) is used. Since the nuclei are 
relatively heavy objects, quantum mechanical effects are often insignificant, in which case Eq 
1.3  can be replaced by Newton’s equation of motion: − 𝑑𝑉𝑑𝑅 = 𝑚 𝑑!𝑅𝑑𝑡!  
      (1.4) 
The solution of Eq 1.4 using an empirical fit to the potential energy surface E(R) is called 
molecular dynamics. Molecular mechanics ignores the time evolution of the system and instead 
focuses on finding particular geometries and their associated energies or other static properties. 
This includes finding equilibrium structures, transition states, relative energies, and harmonic 
vibrational frequencies [MSI, 1998]. 
 
Forcefield 
The forcefield contains the necessary building blocks for the calculations of energy and force:  -­‐ a list of atom types; -­‐ a list of atomic charges; -­‐ atom-typing rules; 
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-­‐ functional forms for the components of the energy expression; -­‐ parameters for the function terms; -­‐ for some forcefield, rules for generating parameters that have not been explicitly 
defined; -­‐ for some forcefield, a defined way of assigning functional forms and parameters. 
The forcefield commonly used for describing molecules employs a combination of internal 
coordinates and terms (bond distances, bond angles, torsions, etc.), to describe part of the 
potential energy surface due to interactions between bonded atoms, and nonbond terms. The 
functional forms range from simple quadratic forms to Morse functions, Fourier expansions, 
Lennard-Jones potentials, etc. 
The goal of the forcefields is to describe entire classes of molecules with reasonable accuracy. 
In a sense, the forcefield interpolates and extrapolates form the empirical data of the small set 
of models used to parameterize the forcefield to a larger set of related models. Some forcefields 
aim for high accuracy for a limited set of element types, thus enabling good prediction of many 
molecular properties. Other forcefields aim for the broadest possible coverage of the periodic 
table, with necessarily lower accuracy. 
The physical significance of most of the types of interactions in a forcefield is easily 
understood, since describing a model’s internal degrees of freedom in terms of bonds, angles, 
and torsions seems natural. The analogy of vibrating balls connected by springs to describe 
molecular motion is equally familiar. However, it must be remembered that such models have 
limitations. Consider for example the difference between such a mechanical model and 
quantum mechanical bonds. 
Covalent bonds can, to a first approximation, be described by the harmonic oscillator in Figure 
1.5. 
 
 
 
Figure 1.5. Energy and probability of a mechanical and quantum particle in a harmonic energy well. The energy is 
indicated by the heavy lines and probability by the thin lines. The total energy of the system is indicated by the pale 
horizontal line. The classical (mechanical) probability is highest when the particle reaches it maximum potential 
energy (zero velocity) and drops to zero between these points. The quantum mechanical probability is highest where 
the potential energy is lowest, and there is a finite probability that the particle can be found outside the classical limits 
(pale vertical lines) [from MSI, 1998]. 
 
A ball poised at the intersection of the light horizontal line with the parabolic energy surface 
would begin to roll down, converting its potential energy to kinetic energy until, exactly at the 
same height as it had started, it would pause momentarily before rolling back. The interchange 
of kinetic and potential energy in such a mechanical system is intuitive. 
The probability of finding the ball at any point along its trajectory is inversely proportional to 
its velocity at that point (which is opposite to the probability for a real atom). The probability is 
plotted above the parabolic curve. The probability is greatest near the high-energy limits of its 
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trajectory (where it is moving quickly), because the total energy cannot exceed the initial 
potential energy defined by the intersection of the total energy with the parabola. 
Describing a quantum mechanical “trajectory” is impossible [Heisemberg, 1930], because the 
uncertainty principle prevents an exact, simultaneous specification of both position and 
momentum. However, the probability that the quantum mechanical ball will be at a given point 
on the parabola can be quantified. The quantum mechanical probability function plotted in the 
right panel of Figure 1.5 is very different from the mechanical systems. First, the highest 
probability is at the energy minimum, which is the opposite of the mechanical case. Second, 
the quantum mechanical ball can actually be found beyond the classical limits imposed by total 
energy of the system (tunneling). Both these properties can be attributed to the uncertainty 
principle. 
With such a different qualitative picture of fundamental physical principles, it is reasonable to 
use a mechanical approach for obviously quantum mechanical entities like bonds? In practice, 
many experimental properties such as vibrational frequencies, sublimation energies, and crystal 
structures can be reproduced with a forcefield, not because the systems behave mechanically, 
but because the forcefield is fit to reproduce relevant observables and therefore includes most 
of the quantum effects empirically. Nevertheless it is important to appreciate the fundamental 
limitations of a mechanical approach. 
Applications beyond the capability of most forcefield methods include: -­‐ electronic transitions (photon absorption); -­‐ electron transport phenomena; -­‐ proton transfer (acid/base reactions). 
The true power of the atomistic description of a model embodied in the energy expression lies 
in the three major areas: -­‐ the first is that forcefield-based simulations can handle large systems, since these 
simulations are several orders of magnitude faster (and cheaper) than quantum-based 
calculations. Forcefield-based simulations can be used for studying condensed-phase 
molecules, macro-molecules, crystal morphology, inorganic and organic interphases, 
etc., where the properties of interest are not sensitive to quantum effects (e.g., phase 
behaviour, equations of state, bond energies, etc); -­‐ the second is the analysis of the energy contributions at the level of individual 
interactions, or classes thereof. For instance, it is possible to decompose the energy 
into bond energies, angle energies, nonbond energies, etc. or even to the level of a 
specific hydrogen bond or van del Waals contact, in order to understand a physical 
observable or to make a prediction; -­‐ the third area, which is described as application of constraints and restraints, lies in the 
modification of the energy expression to bias the calculation. One can impose 
constraints (absolute conditions), such as fixing an atom in space and not allowing it 
to move. The user can also add extra terms to the energy expression to restraint or 
force the system in certain ways. For instance, by adding an extra torsion potential to 
a particular bond, it is possible to force the torsion angle toward a desired value. (One 
can apply constraints also for quantum-based energy calculations) [MSI, 1998]. 
 
The energy expression 
The actual coordinates of a model combined with the forcefield data create the energy 
expression (or target function) for the model. This energy expression is the equation that 
describes the potential energy surface of a particular model as a function of its atomic 
coordinates. The potential energy of a system can be expressed as a sum of valence (or bond), 
cross-term, and non-bond interactions. 
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𝐸!"!#$ = 𝐸!"#$%&$ + 𝐸!"#$$%&"' + 𝐸!"!#"!$ 
   (1.5) 
The energy of valence interactions is generally accounted for by diagonal terms, namely, bond 
stretching (𝐸!"#$), valence angle vending (𝐸!"#$%), dihedral angle torsions (𝐸!"#$%"&) and 
inversion (𝐸!"#$%&!'"  o  𝐸!!" ) terms, which are part of nearly all forcefields for covalent 
systems. A Urey-Bradley term (𝐸!") may be used to account for interactions between atom 
pairs involved in 1-3 configurations (i.e., atoms bound to a common atom): 
 𝐸!"#$%&$ = 𝐸!"#$ + 𝐸!"#$% + 𝐸!"#$%"& + 𝐸!!" + 𝐸!" 
(1.6) 
Modern (second-generation) forcefields generally achieve higher accuracy by including cross-
terms to account for such factors as bond or angle distortions caused by nearby atoms. Cross-
terms can include the following terms: stretch-stretch, stretch-bend-stretch, bend-bend, torsion-
stretch, torsion-bend-bend, bend-torsion-bend, stretch-torsion-stretch. 
The energy of interaction between non-bonded atoms is accounted for by van der Waals 
(𝐸!"#), electrostatic (𝐸!"#$"%&), and (on some older forcefields) hydrogen bond (𝐸!!"#$) 
terms: 
 𝐸!"!#"!$ = 𝐸!"# + 𝐸!"#$"%& + 𝐸!!"#$ 
(1.7) 
Restraints that can be added to an energy expression include distance, angle, torsion, and 
inversion restraints. Restraints are useful if one is, for example, interested in the structure of 
only part of a model. As a simple example of a complete energy expression, consider the 
following equation, which might be used to describe the potential energy surface of a water 
model: V R = 𝐾!! 𝑏 − 𝑏!!! ! + 𝐾!! 𝑏! − 𝑏!!! ! + 𝐾!!! Θ − Θ!!!! ! 
 (1.8) 
Where 𝐾!!, 𝑏!!! , 𝐾!!! and Θ!!!!  are parameters of the forcefield, b is the current bond length of 
one O-H bond, b’ id the length of the other O-H bond, and O is the H-O-H angle. In this 
example, the forcefield defines: -­‐ the coordinates to be used (bond lengths and angles) -­‐ the functional form (a simple quadratic in both types of coordinates) -­‐ the parameters (the force constants 𝐾!! and 𝐾!!!, as well as the reference values 𝑏!!!  
and Θ!!!! ) 
The reference O-H bond length and reference H-O-H angle are the values for an ideal O-H 
bond and H-O-H angle at zero energy, which is not necessarily the same as their equilibrium 
values in a real water molecule. 
Eq 1.8 is an example of an energy expression as set up for a simple molecule. Eq 1.9 is an 
example of the corresponding general, summed forcefield function: 
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 (1.9) 
The first four terms in this equation are sums that reflect the energy needed to stretch bond (b), 
bend angle (Θ) away from their reference values, rotate torsion angle (Φ) by twisting atoms 
about the bond axis that determines the torsion angle, and distort planar atoms out of the plane 
formed by the atoms they are bonded to (𝜒). The next five terms are cross-terms that account 
for interactions between the four types of internal coordinates. The final term represents the 
non-bond interactions as a sum of repulsive and attractive Lennard-Jones terms as well as 
Coulombic terms, all of which are a function of the distance 𝑟!"between atom pairs. The 
forcefield defines the functional form of each term in this equation as well as the parameters 
such as 𝐷!, 𝛼, and 𝑏!. The forcefield also defines internal coordinates such as 𝑏, Θ, and 𝜒 as a 
function of the Cartesian atomic coordinates, although this is not explicit in Eq 1.9. We should 
note that the energy expression in Eq 1.9 is cast in a general form. The true energy expression 
for a specific model includes information about the coordinates that are included in each sum. 
For example, it is common to exclude interactions between bonded and 1-3 atoms in the 
summation representing the non-bond interactions. Thus a true energy expression might 
actually use a list of allowed interactions rather than the full summation implied in Eq 1.9 
[MSI, 1998]. 
 
Many types of forcefield 
Forcefields can be divided into the following categories: -­‐ classical, first-generation forcefield applicable mainly to biochemistry; -­‐ second-generation forcefields capable of predicting many properties; -­‐ rule-based forcefields applicable to a broad range of elements in the periodic table; -­‐ specific-purpose forcefields that are narrowly applicable to particular applications or 
types of models. 
 
Energy minimization 
The potential energy function of a (macro)molecular system is a very complex landscape in a 
large number of dimensions. For example, the energy of a conformation of ethane is a function 
of the 18 internal coordinates or 24 Cartesian coordinates that are required to completely 
specify the structure. The way in which the energy varies with the coordinates is referred to as 
the potential energy surface. For a system with N atoms the energy is thus a function of 3𝑁 − 6 
internal or 3𝑁 Cartesian coordinates. It is therefore impossible to visualize the entire potential 
energy surface except for some simple cases where the potential energy is a function of just 
one or two coordinates. For example, the van der Waals energy of two argon atoms depends 
upon just one coordinate: the interatomic distance. Sometimes the user may wish to visualize 
just a part of the potential energy surface. For example, suppose one takes an extended 
conformation of pentane and rotate the two central carbon-carbon bonds so that the torsion 
angles vary from 0° to 360°, calculating the potential energy of each structure generated. The 
potential energy in this case is a function of just two variables and can be plotted as a contour 
diagram or as a isometric plot, as shown in Figure 1.6. 
 
The potential energy surface has one deepest point, the global energy minimum, associated 
with the lowest energy, and a very large number of local minima. Minimum energy 
arrangements of the atoms correspond to stable states of the systems; any movement away 
from a minimum gives a configuration with a higher energy. At the minima all derivatives of 
the potential energy function with respect to the coordinates are zero and all second derivatives 
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are non-negative. The matrix of second derivatives, which is called Hessian matrix, has non-
negative eigenvalue; only the collective coordinates that correspond to translation and rotation 
(for an isolated molecule) have zero eigenvalue. In between the local minima there are saddle 
points, where the Hessian matrix has only one negative eigenvalue. These points are the 
mountain passes through which the systems can migrate from one local minimum to another. 
 
 
 
Figure 1.6.  Variation in the energy of pentane with the two torsion angles indicated and represented as a contour 
diagram and isometric plot. Only the lowest-energy regions are shown. (from Leach, 2001) 
 
Knowledge of all local minima, including the global one, and of all saddle points would enable 
us to describe the relevant structures and conformations and their free energies, as well as the 
dynamics of structures transitions. A minimization algorithm is used to identify those 
geometries of the system. Unfortunately, the dimensionality of the configurational space and 
the number of the local minima is so high that it is impossible to sample the space at a 
sufficient number of points to obtain a complete survey. In particular, no minimization method 
exists that guarantees the determination of the global minimum in any practical amount of 
time. However, given a starting configuration, it is possible to find the nearest local minimum. 
Nearest in this contest does not always imply nearest in a geometrical sense (i.e. the least sum 
of square coordinate differences), but means the minimum that can be reached by 
systematically moving down the steepest local gradient [Van der Spoel et al., 2006]. 
The minimization problem can be formally stated as follows: given a function 𝑓 which depends 
on one or more independent variables 𝑥!, 𝑥!, …, 𝑥!, find the value of those variables where 𝑓 
has a minimum value. At the minimum point the first derivative of the function with respect to 
each of the variables is zero and the second derivatives are positive: 
 ∂𝑓∂𝑥! = 0                                                                 ∂!𝑓∂𝑥!! > 0 
(1.10) 
The functions of most interest to us will be the quantum mechanics or molecular mechanics 
energy with the variables 𝑥! being the Cartesian or the internal coordinates of the atoms. 
Molecular mechanics minimizations are nearly always performed in Cartesian coordinates, 
 Informatics Introduction 
	  32	  
with which the energy is a function of 3𝑁 variables; it is more common to use internal 
coordinates with quantum mechanics. For analytical functions, the minimum of a function can 
be found using standard calculus methods. However, this is not generally possible for 
molecular systems due to the complicated way in which the energy varies with the coordinates. 
Rather, minima are located using numerical methods, which gradually change the coordinates 
to produce configurations with lower and lower energies until the minimum is reached. 
Minimization algorithms can be classified into two groups: those, which use derivatives of the 
potential energy with respect to the coordinates and those, which do not. Derivatives can be 
useful because they provide information about the shape of the potential energy surface, and, if 
used properly, they can significantly enhance the efficiency with which the minimum is 
located.  There are many factors that must be taken into account when choosing the most 
appropriate algorithm (or combination of algorithms) for a given problem; the ideal 
minimization algorithm is one that provides the answer as quickly as possible, using the least 
amount of memory. No single minimization method has yet proved to be the best for all 
molecular modeling problems. In particular, a method that works well with quantum mechanics 
may not be the most suitable for use with molecular mechanics. This is party because quantum 
mechanics is usually used to model systems with fewer atoms than molecular mechanics; some 
operations that are integral to certain minimization procedures (such as matrix inversion) are 
trivial for small systems but formidable for systems containing thousands of atoms. Quantum 
mechanics and molecular mechanics also require different amounts of computational effort to 
calculate the energies and the derivatives of the various configurations. Thus an algorithm that 
takes many steps may be appropriate for molecular mechanics but inappropriate for quantum 
mechanics. 
Most minimization algorithms can only go downhill on the potential energy surface and so they 
can only locate the minimum that is nearest (in a downhill sense) to the starting point. To 
locate more than one minimum or to locate the global potential energy minimum usually 
requires a means of generating different starting points, each of which is then minimized. Some 
specialized minimization methods can make uphill moves to seek minima lower in energy that 
the nearest one, but no algorithm has yet proved capable of locating the global energy 
minimum from an arbitrary starting position. 
The input to a minimization program consists of a set of initial coordinates for the systems. The 
initial coordinates may come from a variety of sources. They may be obtained from an 
experimental technique, such as X-ray crystallography or NMR. In other cases a theoretical 
method is employed, such as a conformational search algorithm. A combination of 
experimental and theoretical approaches may also be used. For example, to study the behaviour 
of a protein in water one may take an X-ray structure of the protein and immerse it in a solvent 
bath, where the coordinates of the solvent molecules have been previously obtained from a 
Monte Carlo or molecular dynamics simulation [Leach, 2001]. 
 
Minimization algorithms 
Three possible energy minimization methods are: -­‐ those that require only function evaluations. Examples are the simplex method and its 
variants. A step is made on the basis of the results of previous evaluations. If 
derivative information is available, such methods are inferior to those that use this 
information; -­‐ those that use derivative information. Since the partial derivatives of the potential 
energy with respect to all coordinates are known in MD programs (these are equal to 
minus forces) this class of methods is very suitable as modification of MD programs. -­‐ those that use second derivative information as well. These methods are superior in 
their convergence properties near the minimum: a quadratic potential function is 
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minimized in one step. The problem is that for N particles a 3𝑁 x 3𝑁 matrix must be 
completed, stored and inverted. Apart from the extra programming to obtain second 
derivatives, for most systems of interest this is beyond the available capacity. There 
are intermediate methods building up the Hessian matrix on the fly, but they also 
suffer from excessive storage requirements. 
The steepest descent method is of the second class. It simply takes a step in the direction of the 
negative gradient (hence in the direction of the force), without any consideration of the history 
built up in previous steps. The step size is adjusted such that the search is fast but the motion is 
always downhill. This is a simple and sturdy method: its convergence can be quite slow, 
especially in the vicinity of the local minimum. Although steepest descent is certainly not the 
most efficient algorithm for searching, it is robust and easy to implement. The vector 𝑟  is 
defined as the vector of all 3N coordinates. Initially a maximum displacement ℎ! (e.g. 0.01nm) 
must be given. First the force F and potential energy are calculated. New positions are 
calculated by: 𝑟!!! = 𝑟! + 𝐹!max   ( 𝐹! ) ℎ! 
 (1.11) 
where  ℎ! is the maximum displacement and 𝐹!  is the force, or the negative gradient of the 
potential V. The notation max  ( 𝐹! ) means the largest of the absolute values of the force 
components. The forces and energy are again computed for the new positions. If (𝑉!!! < 𝑉!), 
the new positions are accepted and ℎ!!! = 1.2ℎ!. If (𝑉!!! ≥ 𝑉!), the new position are rejected 
and ℎ! = 0.2ℎ!. The algorithm stops when either a user-specified number of force evaluations 
has been performed (e.g. 100), or when the maximum of the absolute values of the force 
(gradient) components is smaller than a specified value 𝜖. Since force truncation produces 
some noise in the energy evaluation, the stopping criterion should not be made too tight to 
avoid endless iterations. A reasonable value for 𝜖 can be estimated from the root mean square 
force f a harmonic oscillator would exhibit at a temperature T. This value is:  
 𝑓 = 2𝜋𝜐 2𝑚𝑘𝑇 
 (1.12) 
where 𝜐 is the oscillator frequency, m the (reduced) mass, and k Boltzmann’s constant. For a 
weak oscillator with a wave number of 100 cm-1 and a mass of 10 atomic units, at a 
temperature of 1 K, f = 7.7 kJmol1nm1. A value for 𝜖 between 1 and 10 is acceptable.  
Conjugate gradient is slower than steepest descent in the early stages of the minimization, but 
becomes more efficient closer to the energy minimum, The parameters and stop criterion are 
the same as for steepest descent. The conjugate gradient method [Zimmerman, 1991] uses 
gradient information from previous steps. In general, steepest descents will bring close to the 
nearest local minimum, but performs worse far away from the minimum [Lindahl et al., 2001]. 
 
Classical molecular dynamics simulations 
While minimization computes the forces on the atoms and changes their positions to minimize 
the interaction energies, dynamics computes forces and moves atoms in response to the forces. 
MD simulations solve Newton’s equations of motion for a system of N interacting atoms: 
 𝑚! ∂!𝑟!∂t! = 𝐹! , 𝑖 = 1…𝑁 
 (1.13) 
The forces are the negative derivatives of a potential function V (r1, r2, …, rn): 
 
 Informatics Introduction 
	  34	  
𝐹! = ∂𝑉∂𝑟! 
 (1.14) 
The equations are solved simultaneously in small timesteps. The systems is followed for some 
time, taking care that the temperature and pressure remain at the required values, and the 
coordinates are written to an output file at regular intervals. The coordinates as a function of 
time represent a trajectory of the systems. After initial changes, the system will usually reach 
an equilibrium state. By averaging over an equilibrium trajectory many macroscopic properties 
can be extracted from the output file. 
Dynamics simulations are useful in studies of the time evolution of a variety of systems at non-
zero temperatures, for example, biological molecules, polymers, or catalytic materials, in a 
variety of states, for examples, crystals, aqueous solutions, or in the gas phase. 
The major applications of molecular dynamics are: -­‐ performing conformational searches. During dynamics, a system undergoes 
conformational and momentum changes so that different parts of the phase space 
accessible to the model can be explored. The conformational search capability of 
dynamics is one of its most important uses; -­‐ generating statistical ensembles. By providing several mechanisms for controlling the 
temperature and pressure of simulated systems, molecular dynamics allows the 
generation of statistical ensembles from which various energetic, thermodynamic, 
structural and dynamics properties can be calculated. For such studies, it is important 
that the calculation visits various conformational states with the correct statistical 
frequency; -­‐ studying the motions of molecules. Although modern crystallography has provided a 
window into the static structure of both small and large molecules, the thought of 
intermolecular collisions and conformational variation is always present. After all, 
building of substrates by proteins, folding of proteins and peptides into unique shapes, 
the dynamic behavior of polymers, and chemical reactions themselves would be 
inconceivable without the concept of molecular motion. Studies of model motions can 
be used to derive properties such as diffusion coefficients. 
Other approaches to simulating molecular motion and generating conformational searches 
exist. For example, a dynamics trajectory can be constructed from a set of normal modes to 
represent the vibrations of a model. While this is a fast method, it is restricted to harmonic 
motion about a single energy minimum. An approach to doing conformational searches is the 
Monte Carlo method. While this method can sample conformational space so as to produce 
meaningful statistical ensembles, it does not provide dynamic information about the model, 
since particles of the model system are simply moved randomly according to some statistical 
rules [MSI, 1998]. 
It is useful at this point to consider the limitations of MD simulations: -­‐ the simulations are classical: 
using Newton’s equation of motion automatically implies the use of classical 
mechanics to describe the motion of atoms. This is all right for most atoms at normal 
temperatures, but there are exceptions. Hydrogen atoms are quite light and the motion 
of protons is sometimes of essential quantum mechanical character. For example, a 
proton may tunnel through a potential barrier in the course of a transfer over a 
hydrogen bond. Such processes cannot be properly treated by classical dynamics. 
Liquid helium at low temperature is another example in which classical mechanics 
breaks down. The statistical mechanics of a classical harmonic oscillator differs 
appreciably from that of a real quantum oscillator when the resonance frequency 𝜈 
approximates or exceeds 𝑘!𝑇 ℎ . Now at room temperature the wavenumber 
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𝜎 = 1 𝜆 = 𝜈 𝑐  at which ℎ𝜈 = 𝑘!𝑇 is approximately 200 cm-1. Thus all frequencies 
higher than 100 cm-1 may misbehave in classical simulations. This means that 
practically all bond and bond-angle vibrations are suspect, and even hydrogen-bonded 
motions as translation or librational H-bond vibrations are beyond the classical limit. 
To circumvent these limitations, apart from real quantum-dynamical simulations, one 
can do one of two things: 
(a) If performing MD simulations using harmonic oscillators for bonds, one should 
make corrections to the total internal energy   𝑈 = 𝐸!"# + 𝐸!"# and specific heat 𝐶! (and to entropy S and free energy A or G if 
those are calculated). The corrections to the energy and specific heat of a one-
dimensional oscillator with frequency 𝜈 are [McQuarrie, 1976]: 
 𝑈!" = 𝑈!" + 𝑘𝑇 12 𝑥 − 1 + 𝑥𝑒! − 1  
 (1.15)   𝐶!!" = 𝐶!!" + 𝑘 𝑥!𝑒!(𝑒! − 1)! − 1  
 (1.16) 
where 𝑥 = ℎ𝜈 𝑘𝑇. The classical oscillator absorbs too much energy (kT), while 
the high frequency quantum oscillator is in its ground state at the zero-point 
energy level of !! ℎ𝜈. 
(b) One can treat the bonds (and bond angles) as constraints in the equation of 
motion. The rationale behind this is that a quantum oscillator in its ground state 
resembles a constrained bond more closely than a classical oscillator. A good 
practical reason for this choice is that the algorithm can use larger timesteps when 
the highest frequencies are removed. In practice the timestep can be made four 
times as large when bonds are constrained than when they are oscillators [Van 
Gunsteren & Berendsen, 1977]. The flexibility of the latter is rather essential to 
allow for the realistic motion and coverage of configurational space [Van 
Gunsteren & Berendsen, 1977]. -­‐ electrons are in the ground state.  
In MD its common to use a conservative forcefield that is a function of the positions 
of atoms only. This means that the electronic motions are not considered: the electrons 
are supposed to adjust their dynamics instantly when the atomic positions change (the 
Born-Oppenheimer approximation), and remain in their ground state. This is almost 
always correct but, of course, electron transfer process and electronically excited 
states can not be treated. Neither can chemical reactions be treated properly. -­‐ forcefield are approximate. -­‐ Forcefield provide the forces. They are not really a part of the simulation method and 
their parameters can be user-modified as the need arises or knowledge improves. But 
the form of the forces that can be used in a particular program is subject to limitations. 
The majority of the forcefields is pair-additive (apart from long-range Coulomb 
forces), cannot incorporate polarizabilities, and does not contain fine-tuning of bonded 
interactions - but is quite useful and fairly reliable for bio-macromolecules in aqueous 
solution. -­‐ the forcefield is pair-additive. 
This means that all non-bonded force result from the sum of non-bondend pair 
interactions. Non pair-additive interactions, the most important example of which is 
interaction through atomic polarizability, are represented by effective pair potentials. 
 Informatics Introduction 
	  36	  
Only average non pair-additive contributions are incorporated. This also means that 
the pair interactions are not pure, i.e., they are not valid for isolated pairs or for 
situations that differ appreciably from the test systems on which the models were 
parameterized. In fact, the effective pair potentials are generally adequate. But the 
omission of polarizability also means that electrons in atoms do not provide a 
dielectric constant as they should. For example, real liquid alkanes have a dielectric 
constant of slightly more than 2, which reduces the long-range electrostatic interaction 
between (partial) charges. Thus the simulations will exaggerate the long-range 
Coulomb terms. -­‐ long-range interactions are cutoff. 
MD programs always use a cutoff radius for the Lennard-Jones interactions and 
sometimes for the Coulomb interactions as well. Due to the minimum-image 
convention (only one image of each particle in the periodic boundary conditions is 
considered for a pair interaction), the cutoff range cannot exceed half the box size. 
That it still sufficient for large systems, and trouble is only expected for systems 
containing charged particles. But there can be accumulation of charges at the cutoff 
boundary or very wrong energies. For such systems one should consider using one of 
the implemented long-range electrostatic algorithms, such as particle-mesh Ewald 
[Essmann et al., 1995; Darden et al., 1993]. -­‐ boundary conditions are unnatural. 
Since system size is small (even 10 000 particles is small), a cluster of particles will 
have a lot of unwanted boundary with its environment (vacuum). When simulating 
bulk systems, periodic boundary conditions are used to avoid real phase boundaries. 
But liquids are not crystals, so something unnatural remains. For large systems the 
errors are small, but for small systems with a lot of internal correlation, the periodic 
boundaries may enhance internal correlation. This is especially important when using 
lattice sums for long-range electrostatics, since these are known to sometimes 
introduce extra ordering [Van der Spoel et al., 2006]. 
 
Molecular dynamics (MD), Monte Carlo (MC) simulations, or hybrids thereof are general 
methods to generate a physically meaningful ensemble of conformations. These methods rely 
on a suitably well-parameterized force ﬁeld that describes the forces to which the atoms in the 
system are subject. A trajectory is generated, typically at constant temperature, and the 
resulting conformations can be subjected to clustering and further analysis. These methods are 
general and can work with large, complex, multicomponent systems. However, one serious 
drawback is that they explore the conformation space very slowly, since most of the simulation 
time is spent around the equilibrium energy state(s) and low frequency conformation 
transitions are observed relatively rarely. Special techniques can been used, e.g., for 
polypeptide chains, to greatly improve the sampling properties of Monte Carlo; however, the 
long simulation times make MD and MC simulations more suitable for the thermodynamic 
analysis of molecular systems rather than for conformational analysis. 
 
Low Mode molecular dynamics 
The problem of protein folding is a long-time studied and fascinating topic. The idea that the 
three-dimensional protein structure is determined by its primary structure, i.e. by the 
physicochemical properties of the amino acids composing the biopolymer, was already 
hypothesized in the 30’s. Anfinsen, with his experiment, demonstrated that a denatured enzyme 
is able to refold and to completely recover its biological activity [Anfinsen 1973]. Since the 
three-dimensional structure of a protein is closely related to its sequence, it seems 
straightforward to compute its structure by a purely biophysical-based 'brute-force' approach. 
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However, protein folding does not seem to take place in this exhaustively explorative fashion 
since, according to Levinthal's evaluations, a very small protein made of 100 residues should 
spend approximately 1027 years to sample all its conformational space [Levinthal 1969]. The 
fact that protein folding time is in the order of magnitude of µs to ms suggests that other factors 
can drive this process. Different hypotheses were put forward about the molecular mechanisms 
of protein folding. The most common ones make reference to kinetics or to thermodynamics, 
such as classical molecular dynamics. However, the exhaustive search of the conformational 
space is a computationally demanding procedure, especially for big proteins, and cannot 
actually be afforded through either classical MD or random walk approaches. For this reason, 
scientists developed alternative methods aimed at empowering the exploration of the protein 
conformational space, including approaches based on the guided search of the conformational 
space. In 1996, Kolossvàry and Guida reported on Low Mode Search (LowMode), which is a 
conformational search method based on low-frequency modes [Kolossvary 1996]. 
In this method, for each iteration the molecular system is perturbed along low-frequency 
vibrational mode directions in a systematic way. The perturbed conformation is then subjected 
to coordinate optimization. The fundamental principle of low mode search is very appealing: 
use low-frequency mode transitions to “hop” from one low-energy state to another. An 
assumption is made that such transitions will lead to a full exploration of the low energy 
conformation ensemble; however, this assumption is physically motivated and appears 
reasonable. LowModeMD is not intended to be a high-throughput method, and emphasis is 
placed on the efﬁcient production of low-strain-energy local minima of a potential energy 
function. The method is stochastic, in that there is no attempt to systematically follow 
vibrational mode directions. 
In comparison with classical MD, it features a very efficient way for searching for minima 
troughs on the potential energy surface. LowModeMD can be used for studying the flexibility 
of structural protein regions, such as loops, or for the modeling of ligands in the binding 
pocket. 
 
Protein structure modeling 
Protein structures are primarily obtained using X-ray crystallography or nuclear magnetic 
resonance (NMR) spectroscopy, but these methods are time consuming, expensive, and not 
feasible for all proteins. 
All the data about the already known proteins are organized in public databases classified in 
sequence and structure databases. Among these, we just recall the most relevant ones: 
Sequence:  UniProt [http://www.uniprot.org/] 
NCBI [http://www.ncbi.nlm.nih.gov/guide/proteins/] 
Structure:  RCSB PDB [http://www.rcsb.org/pdb/home/home.do] 
  CATH [http://www.cathdb.info/]  
SCOP [http://scop.mrc-lmb.cam.ac.uk/scop/]  
The Universal Protein Resource (UniProt) provides the scientific community with a 
comprehensive, high-quality and freely accessible resource of protein sequences and functional 
information. The National Center for Biotechnology Information (NCBI) also maintains a non-
redundant database of protein primary structures from several species. RCSB (Research 
Collaboratory for Structural Bioinformatics) PDB (Protein Data Bank) contains three-
dimensional structures of biopolymers solved mainly through X-ray crystallography and NMR. 
At the start of 2012, PDB contains more than 80 000 structures. The CATH database is a 
manually-managed classification (supported by automated techniques) of protein domain 
structures. The SCOP database provides a detailed and comprehensive description of the 
structural and evolutionary relationships between all proteins whose structure is known. As 
reported in its web site, it provides a broad survey of all known protein folds, detailed 
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information about the close relatives of any particular protein, and a framework for future 
research and classification. As seen from the above, only a small number of protein structures 
have been solved, but the knowledge of protein structure is a critical step toward understanding 
their functions. 
The structural properties of a protein are univocally determined by its primary structure, i.e. its 
amino acid sequence. For several years, scientists have been studying the possibility to predict 
the three-dimensional structure of a protein just starting from its amino acid sequence. This is 
not a plain issue but, with time, useful methods for predicting the structural properties, local or 
global, of a protein from its sequence have been significantly improved.  
 
The protein structure modeling moves from the idea that there are only around 2,000 distinct 
protein folds in nature, though there are many millions of different proteins and then that some 
tertiary structures are shared between different proteins.  
The comparative protein modelling indeed provides the use of existing structures solved as a 
starting point for the construction of new structural models. The approach to be used for 
building a three-dimensional protein model depends upon the data that can be retrieved from 
literature. The most used and most accurate procedure is homology or comparative modeling; it 
is based on the idea that proteins with similar sequence share the same folding. The necessary 
conditions for producing a good three-dimensional model through the homology modeling 
approach is that the similarity between the target sequence and the template structure(s) is 
detectable and that a reliable alignment between them can be obtained. 
If you are unable to identify evolutionarily related templates to the protein of interest by 
sequence alignment, a good alternative strategy can be the protein threading approach. This 
method scans the amino acid sequence of an unknown structure against a database of solved 
structures and tries to adapt the primary structure on all the tertiary structure available, 
assigning a folding score according to a scoring function, which evaluates the compatibility of 
the sequence to the structures. 
Nevertheless, in some cases, both comparative modeling strategies can fail, principally when 
the evolutionary distance between query and template is too high. In these cases, possible 
solutions are ab initio or de novo protein modelling methods. These methods build three-
dimensional protein models "from scratch", i.e., based on physical principles rather than on 
previously solved structures. However, these procedures appear to have a high computational 
cost and to be time-consuming. To predict protein structure de novo for larger proteins will 
require better algorithms and larger computational resources like those afforded by either 
powerful supercomputers or distributed computing. 
Once modelled the protein backbone, it is necessary an accurate packing of the amino acid side 
chains. Different methods exist to predict the correct side-chain geometry, building a set of 
different side chain conformations known as "rotamers", and then energetically evaluate them. 
A very interesting method for protein model construction is Robetta [Kim 2004]. The Robetta 
server is an automated protein structure prediction service offered by the Baker laboratory for 
non-commercial ab initio and comparative modelling [Raman 2009]. 
First, Robetta searches for structural homologs using different algorithms, such as BLAST or 
PSI-BLAST, then parses the target sequence into individual domains, or independently folding 
units of proteins, by matching the sequence to structural families in the Pfam database; if 
domains present structural homology with known proteins, Robetta follows a "template-based 
model" protocol. Domains without structural homologs are modelled by Rosetta de novo 
method. From all these fragments, Robetta produces a decoy (possible structure) to be then 
energetically evaluated. The final structure prediction is selected by taking the lowest energy 
model as determined by a low-resolution Rosetta energy function. Finally, side-chain 
contributions are modelled using a protocol for Monte Carlo conformational search. 
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Mutagenesis 
Mutagenesis studies on proteins are carried out with different aims. They are useful in 
deciphering the structure/function relationships, in predicting the effect of a mutation on the 
development of a specific pathology, in the evaluation of the physicochemical effects of 
specific mutations on protein folding and stability, etc. The effect of single point mutations can 
be estimated keeping into account the distance from active residues, the change in the local 
hydrophobic/hydrophilic balance, the change in steric hindrance, the disruption of salt bridges, 
etc. 
Several approaches for studying the effects of mutations have been set up, tested, and described 
in literature. Some of them are based on the knowledge of the protein structure; others are just 
based on comparative considerations. A widely used method is PolyPhen-2 [Adzhubei 2010]. 
PolyPhen-2 is an interesting tool that can predict the impact of an amino acid substitution on 
the structure and function of a human protein using straightforward physical and comparative 
considerations. It is based on a pipeline combining multiple sequence alignment with a 
probabilistic classifier based on machine-learning methods.  
When the three-dimensional structures of the target proteins are available, more accurate 
evaluations can be performed. For single point mutations, local structure and energetic 
evaluations can be carried out after side chain repacking. This procedure is more complex if the 
insertion or deletion is larger. Some very efficient sampling methods can be useful in order to 
evaluate the possible conformations allowed after the primary structure modification, for 
instance, the LowMode MD simulations method, applied on the mutated residue and on its 
environment. 
 
Molecular docking 
In computational biology, molecular docking is a method to predict the structure (or structures) 
of the intermolecular complex formed between two or more molecules, or rather, the reciprocal 
preferred orientation of two (or more) interacting molecules. Docking is widely used to predict 
the strength of association (binding affinity) between two molecules.  
Docking is used to investigate on the associations between biologically relevant molecules 
such as proteins, nucleic acids, carbohydrates, and lipids, that play a central role in signal 
transduction. Furthermore, the relative orientation of the two interacting partners may affect the 
type of signal produced (e.g., agonism vs antagonism). For instance, this method is frequently 
used to predict the binding orientation of small putative drug compounds to their protein targets 
in order to evaluate the affinity (and the activity, even if not directly) of these small molecules, 
and hence docking plays a relevant role in the rational design of drugs. 
Considerable efforts have been directed towards improving the methods used to predict 
docking, because of the high biological and pharmaceutical significance of molecular docking 
 
The “docking problem” thus deals with the generation and evaluation of plausible structures of 
intermolecular complexes. The docking problem involves many degrees of freedom. There are 
six degrees of translational and rotational freedom per molecule with respect to another one, as 
well as the conformational degrees of freedom of each molecule.  
This problem can be manually managed, but this “hands-on” approach can be very complex 
and time consuming. Automatic docking algorithms can be less biased than human operators 
and usually consider many more complex possibilities. Various algorithms have been 
developed to tackle the docking problem. These can be characterised according to the number 
of degrees of freedom they ignore. Thus, the simplest algorithms treat the two molecules as 
rigid bodies and explore only the six degrees of translational and rotational freedom. This 
method is named rigid molecular docking, and molecules are treated as rigid objects that 
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cannot change their spatial shape during the docking process. The earliest algorithms for 
docking small molecule ligands into the binding sites of proteins and DNA used this 
approximation; they were developed by Kuntz et al. in 1982 [Kuntz 1982]. 
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A series of large population studies have revealed the existence of a strong inverse correlation 
between plasma levels of high-density lipoprotein cholesterol (HDL-C) and cardiovascular 
risk. Accordingly, HDL has become a major target for the development of novel therapies for 
the treatment of atherosclerotic cardiovascular disease. 
LCAT is the enzyme responsible for the catalysis of the transacylation of the sn-2 fatty acid of 
lecithin to the free 3-0H group of cholesterol, generating cholesteryl ester (CE) and 
lysolecithin. LCAT plays a central role in HDL structure and metabolism and promotes reverse 
cholesterol transport.[Jonas 2000]  
The effect of LCAT on atherogenesis has been controversial, but recent studies [Calabresi 
2009; Holleboom 2010] suggest that the presence of defective LCAT may not preclude 
cholesterol removal from the arterial wall and efficient reverse cholesterol transport. These 
recent data, together with findings in genetic LCAT deficiency, challenge the notion that 
LCAT is atheroprotective and suggest that, despite positive effects on plasma HDL-C 
concentration, elevating LCAT expression and/or activity is not a promising therapeutic 
strategy to reduce cardiovascular risk. On the contrary, decreasing LCAT activity has certainly 
negative effects on plasma HDL-C concentration but possibly positive effects on HDL 
structural function, and may represent a new therapeutic strategy to reduce cardiovascular risk. 
In this perspective, the availability of new potent and selective LCAT inhibitors is mandatory. 
The objective of my studies is the identification of molecules able to modulate the LCAT 
enzyme, with the aim of identifying new drugs for the prevention and treatment of 
atherosclerotic cardiovascular diseases. 
This aim was been realized using a combined approach of computational biology and 
biochemistry tools, based on the followed steps: 
• In silico building of 3D LCAT structure by a combination of comparative and ab 
initio modeling and in silico evaluation of the known mutations impact on the LCAT 
structure/functions. 
• In silico high-throughput screening of putative LCAT modulators and evaluation of 
the effects of LCAT modulators on cholesterol esterification in vitro and in vivo on 
atherosclerosis models. 
Globally, this project will produce innovative pharmacological entities to be further developed 
for a completely new therapeutic approach to the treatment of atherosclerotic cardiovascular 
diseases. 
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3.1	  	   LCAT	  STRUCTURE	   
 
The identification of amino acids relevant in controlling LCAT structure and function is 
mandatory to design a therapeutic strategy to reduce cardiovascular risk that aims at 
modulating the activity of this enzyme. Knowledge of the topology of LCAT or, better, of its 
atomic structure is expected to be very helpful to understand its catalytic mechanism and its 
role in the metabolism of HDL. A molecular tool to perfect the study of the structure/function 
relationship of an enzyme is then the evaluation of the impact of known mutations its the 
activity. Several mutations in the LCAT gene, which result in familial LCAT deficiency (FLD) 
or fish-eye disease (FED), have been described. 
To date, the structure of LCAT has not been resolved experimentally [Jauhiainen 1986; Yang 
1987; Peelman 1999]. The major problems are connected with the enzyme purification from 
human plasma, where LCAT is present in extremely low concentrations and strongly bound to 
lipoproteins. An alternative approach may be protein modeling through in silico procedures. 
LCAT belongs to the α/β hydrolase fold family and shares the Ser/Asp−Glu/His triad with 
lipases, esterases and proteases, but, as already discussed by Peelman et al. in 1998 [Peelman 
1998], modeling LCAT structure faces a number of problems. LCAT lacks appropriate 
templates for a straightforward homology modeling: the protein has a very low sequence 
identity, if a high secondary structure similarity, with respect to all available templates. The 
LCAT N−terminus (residues 73−210) was already modeled on human pancreatic lipase by 
Peelman et al. [Peelman 1998]. The completion of the active site (aa 333−399), which extends 
beyond the modeled N-terminus, was carried out using the coordinates of the corresponding 
residues of C. antarctica lipase; the remaining parts of LCAT were not modeled. Peelman et al 
never made available to the scientific community the spatial coordinates of their LCAT model. 
A new and complete model of LCAT will be appropriate to map and analyze the known 
mutations leading to FLD and FED and to envisage their structural implications. Interesting 
demonstrations on how molecular modelling can be successfully used to predict the functional 
importance of specific amino acids and their mutations are reported in [Campbell 2007; 
Peelman 2001; Razzaghi 2001; Kobayashi 2002].  
In order to build a complete LCAT model, it is important to find better templates among the 
newly crystallized α /β hydrolases and to follow the most up-to-date strategies, such as a 
combined approach that includes secondary structure prediction, folding recognition, and 
‘chimeric’ homology modeling [Weigelt 2010]. In parallel, tools, such as Polyphen and 
Panther [Sunyaev 2001; Thomas 2004; Brunham 2005], that rely on straightforward physical 
principles and perform comparative evaluations, may be used to predict the possible impact of 
various amino acid substitutions on the structure and function of LCAT. 
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3.2	  	   MATERIALS	  AND	  METHODS	  (Theme	  1)	   
 
Comparative modeling 
The human LCAT sequence was downloaded from the UniProt-Protein Knowledgebase 
database [entry UniProt ID: P04180]. Starting from its sequence, a model was built based on 
multiple templates. 
We identified two parts of the protein, a N-terminal ‘domain’, consisting of residues 1-210, and 
a C-terminal ‘domain’, composed of residues 200-416, and we separately submitted both parts 
to the Fold Recognition PSIPRED default procedure. We found 2VTV (PhaZ7depolymerase 
from Paucimonas lemoignei, UniProt ID: Q939Q9. Identity: 19.5%) as a suitable template for 
LCAT N-terminal 'domain' and 2VEO (Lipase A from Candida antarctica, UniProt ID: 
D4PHA8. Identity: 14.5%) as a template for LCAT C-terminal 'domain'. All the modeling 
procedures were carried out with modules of the suite Molecular Operating Environment 
2008.10 (MOE). 
The alignment of the sequences of target and template proteins was produced with the Align 
program of MOE using default parameters and was manually adjusted making reference to 
BLAST outputs. This alignment was set as reference for all the homology modeling 
procedures. 
 
Comparative model building was carried out with the MOE Homology Model program. 2VTV 
was set as template for LCAT residues 1-210 and 2VEO for residues 200-416. Ten 
independent models were built and refined, and then the highest-scoring intermediate model 
was submitted to a further round of energy minimization (EM). Both for the intermediate and 
the final structures the refinement procedures consisted in EM runs based on the AMBER99 
forcefield, with the reaction field solvation model. 
The two disulfide bonds of the protein, between cysteines 50 and 74, and between cysteines 
313 and 356, were created through the MOE Builder module. 
The quality of the final model was carefully checked with the MOE Protein Geometry module 
to make sure that the stereochemical quality of the proposed structure was acceptable. 
In parallel, we submitted the primary structure of LCAT to the Robetta Web Server, using 
default parameters. From the output, we selected the model with correct general topology, 
correct geometry of the catalytic triad, and most favorable setting to form cysteine disulfide 
bridges. 
From the above, we built a chimeric model, setting the previous distant homology modeling 
and the Robetta ab initio model as primary template for residues 1-91; the option ‘Use Selected 
Residues to Override Template(s)’ was checked in order to override the primary template with 
the more appropriate ones only for the selected residues. 
All models were minimized and geometrically and energetically evaluated as described above. 
Both disulfide bonds were set as described above. 
 
 
Binding site analysis 
The LCAT binding site was identified through the MOE Site Finder module, which uses a 
geometric approach to calculate possible binding sites in a receptor starting from its three-
dimensional atomic coordinates. This method is based not on energy models but on alpha 
spheres, which are a generalization of convex hulls [Eldesbrunner 1995]. 
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Mutations 
We built LCAT mutant structures, introducing single mutations through the MOE Mutate 
module. For each mutation, we searched the best side chain orientation using MOE Rotamer 
Explorer module and we performed EM runs. 
To evaluate the impact of mutations on LCAT, we submit the know mutations to two different 
prediction tools available online: Polyphen (polymorphism phenotyping; 
http://genetics.bwh.harvard.edu/pph2/) [Adzhubei 2010] and PANTHER (Protein ANalysis 
THrough Evolutionary Relationships; http://www.pantherdb.org/) [Thomas 2006], using 
default parameters.  
 
Low-mode molecular dynamics 
To evaluate the impact of all the collected mutations on the protein structure  around the 
mutated residue, we applied the low-mode molecular dynamics (LowModeMD) approach, 
focusing a MD trajectory along the low-mode vibrations and searching with high efficiency for 
minima troughs on the potential energy surface. We run these computations with the 
Conformational Search program of MOE Conformations module, which uses an efficient 
implicit method for estimating the low-frequency modes, based on the attenuation of high-
range velocities, as described in detail in [Labute 2010]. 
For both wild-type and mutated amino acid, we selected the nearest residues (closer than 4.5 
Å); these were left free to move during the LowModeMD, whereas the residues more than 4.5 
Å away were fixed (not free to move, but used for the potential calculations); all other residues 
were defined as inert (fixed and not used for calculations). The simulation was carried out with 
default parameters, except for strain cut-off, which was set at 100 kcal/mol. One hundred 
conformations were generated and ranked according to the value of the potential energy of the 
conformation. 
For all the structure produced, potential energy and distance from the reference structure were 
calculated, building a RMSD matrix for each mutation. 
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3.3	  	   RESULTS	  AND	  DISCUSSION	  (Theme	  1)	   
 
LCAT homology modeling 
For the modeling procedure we used the entire sequence of human LCAT; without its signal 
peptide, it consists of 416 amino acids [UniProt ID: P04180]. Submitting the entire sequence of 
LCAT to the PDB Search module of the MOE Suite, using default parameters, no suitable 
template was identified, as reported in Figure 3.1. 
 
 
 
Figure 3.1. Screenshot of MOE-SearchPDB Output after submitting the LCAT entire sequence. 
 
Submitting the same sequence to the Fold Recognition module (GenTHREADER) of the 
PSIPRED server (http://bioinf.cs.ucl.ac.uk/psipred/) did not identify any suitable template, and 
the best matching protein with a solved structure was a hydrolase from Lactobacillus 
plantarum [PDB ID 3LP5, UniProt ID: F9UMW5]. However, the latter shares with LCAT only 
16% identity - a level of similarity insufficient to produce any acceptably accurate model. All 
the identified templates belong to the superfamily fold of α/β-hydrolases, confirming previous 
hypotheses that LCAT belongs to this superfamily. 
The low sequence similarity inside the superfamily is due to the fact that the α/β-hydrolase fold 
is common to a number of hydrolytic enzymes of widely different phylogenetic origin and 
catalytic function. The enzymes are believed to have diverged from a common ancestor, 
preserving only the arrangement of the catalytic residues. All of them present a catalytic triad, 
which is the most conserved structural feature in the fold. This very high sequential and 
topological variability prevented us from recognizing an appropriate template for the homology 
modeling procedures. We had better success after splitting the LCAT primary structure approx. 
in two halves, which allowed the identification of two templates relevant to LCAT distant 
homology modeling. 
 
One of the most innovative strategies to overcome the lack of an appropriate template is 
building homology models of distinct parts of a protein, and then merging them in a single 
model that can be defined ‘chimeric’. This procedure has already been applied successfully by 
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our research group for modeling GPR17, a GPCR involved in ischemic and neurodegenerative 
diseases [Eberini 2011]. 
We thus split LCAT sequence into two parts of comparable length: a N-terminal ‘domain’, 
consisting of residues 1-210, and a C-terminal ‘domain’, composed of residues 200-416. 
Submitting each part to the Fold Recognition PSIPRED procedure, we obtained putative 
templates with better identity than with Lactobacillus plantarum hydrolase, but still under 
30%. 
In Figure 3.2, we report the alignment between LCAT N-terminal 'domain' and 2VTV 
(PhaZ7depolymerase from Paucimonas lemoignei, UniProt ID: Q939Q9. Identity: 19.5%) and 
LCAT C-terminal 'domain' and 2VEO (lipase A from Candida antarctica, UniProt ID: 
D4PHA8. Identity: 14.5%). 
 
 
 
 
 
Figure 3.2. Alignment between LCAT N-terminal 'domain' and 2VTV and LCAT C-terminal 'domain' and 2VEO, 
color coded by similarity (BLOSUM62). 
 
We independently modeled the two parts of LCAT: after loading the PSIPRED alignments into 
the suite MOE, we manually modified them to arrive at the best alignments, to optimize the 
overlapping residues of the two templates, and to minimize the gaps (alignment reported in 
Figure 3.3). 
The parameters for the homology modeling procedures are described in detail under "Materials 
and Methods". One hundred different models of the whole LCAT were built, energetically and 
geometrically scored, and visually inspected. 
 
We carefully checked the overall topology, the geometry (distances and orientation) of the 
catalytic triad, and the distance between the cysteine pairs forming the two disulfide bridges in 
LCAT. The two cystines have key structural roles: the first, Cys 50–74, stabilizes the N-
terminal region, which is the putative sequence for lipoprotein recognition [Peelman 1999]; the 
second, Cys 313–356, is involved in the active site stabilization. 
All the produced models had a correct topology, presenting seven strands in the central β-sheet 
with correct relative orientation. However, of all models produced, only nine structures had the 
cysteines of each pair sufficiently close to build of a disulfide bond. The best model had a 
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distance of 5.5 Å for the pair Cys 50 – Cys 74 and a distance of 5.18 Å for the pair Cys 313 – 
Cys 356. 
 
 
 
Figure 3.3. Global alignment used during the modeling procedures, color-coded by similarity (BLOSUM62). 
 
However, none of these models showed a good geometry for the catalytic triad. This problem 
can be ascribed to the peculiar modeling procedure, since it is not easy to manage at the same 
time the best global alignment with the local geometric constraints imposed by the distances of 
the residues of the catalytic triad. In order to collect more knowledge about LCAT structure 
and to manage these structural issues, we decided to produce, in addition, an ab initio model of 
LCAT; to this purpose, we submitted the primary structure of LCAT, without its signal 
peptide, to the Robetta Web Server, using default parameters. 
Only five of all the generated models had the correct general topology, and two of them lacked 
the correct geometry of the catalytic triad, and so were discarded without further investigations. 
In the three remaining models, the possibility to form cysteine disulfide bridges was evaluated: 
the C-terminal cystine was correctly predicted in all of them, whereas no acceptable predictions 
were obtained for the N-terminal cystine. Looking into the catalytic triad, one of the three 
models presented a very favorable interaction network among the three residues. Furthermore, 
also the localization of the oxyanion hole was correctly predicted. We selected this one as the 
best model obtained from the ab initio Robetta strategy. 
Since the previous homology modeling procedure produced a better structured N-terminal 
'domain', we decided to merge all the structural information obtained from both, the homology 
and the ab initio procedures, in a new, final LCAT model, by replacing the first part of the 
protein (residues 1-91) in the ab initio model with the same residues from the homology 
modeling procedure, as reported in Figure 3.4 
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Figure 3.4. Alignment of different LCAT models: the distant homology model and the ab initio model. In red, the 
portion of LCAT distant homology model takes into account and in blue, the ab initio model used. 
 
This final model structure of LCAT showed the correct topology, the correct mutual orientation 
of the catalytic triad residues, and the correct distance between all the cysteines involved in the 
formation of disulfide bridges. Table 3.1 reports geometric and energetic parameters of the 
final LCAT model. 
Figure 3.5 shows the LCAT structure, after the formation of the two cystine bonds, and after a 
refinement step through energy minimization cycles. Figure 3.6 compares the triad in our 
LCAT model with the catalytic triad of a serine protease. subtilisin, from Bacillus lentus: 
reciprocal distance and residue orientation appear correctly predicted [Kuhn 1998]. 
 
Table 3.1. Scoring, according to different functions, of the final LCAT model [Kcal/mol] 
 
 Contact Energy Packing GB/VI U E sol E ele E vdw E bond 
LCAT 
model -186.76 13.22 -18273.37 2005.04 8100.11 -6947.34 4400.61 4954.83 
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Figure 3.5. Final LCAT structure color-coded by terminus. In evidence the catalytic Serine 181 and the two cystines. 
 
Then, we compared the distances between the catalytic residues with those reported by 
Peelman et al [Peelman Protein Science 1998]: distance between Oγ in Ser 181 and N2 in His 
377 was 5.41 Å versus an expected distance of 2.5 Å, the distance between Oδ in Asp 345 and 
N1 in His 377 is 4.63 Å versus an expected distance of 2.9 Å. The distance between the 
oxyanion hole (Phe 103) and the catalytic triad was 6.75 Å versus an expected distance of 5 Å. 
 
 
 
Figure 3.6. Comparison between Bacillus lentus subtilisin (in grey) and LCAT (colored) catalytic triads [modified 
from Kuhn 1998] 
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Definition of the active site 
So far, the low identity of LCAT with other serine lipases and esterases has hindered the 
acquisition of more details about its structure. 
The role of catalytic serine and histidine has been known since 1986, but the role of other 
putative catalytic amino acids, the presence of the oxyanion hole, and the role of the disulfide 
bridge have been debated for a long time. The catalytic triad has since been characterized as 
consisting of Ser181, Asp 347 and His 377, and Phe103, which is close to the triad, has been 
identified as the oxyanion hole. However, nothing is known at an atomic level of either the 
LCAT binding pocket or the lipoprotein interaction region. 
The catalytic activity of LCAT, which is both phospholipasic and acyltransferasic, requires the 
possibility for both a lecithin and a cholesterol molecule to alternatively enter the catalytic site. 
For this reason we expected to find in the LCAT structure a hydrophobic pocket large enough 
to accomodate the substrates and the product, with an accessible catalytic triad placed at the 
basis of the pocket (active site), and not completely solvent-exposed. 
We used the MOE’s Site Finder tool to identify the binding site of LCAT natural ligands. 
MOE’s Site Finder employs an alpha shape construction whereby points (atoms) on the 
protein’s surface are identified, and the centers of spheres defined by combinations of four 
such points are marked. Where these clusters localize, there are potential binding sites on the 
protein’s surface, excluding potential water sites. This approach falls into the category of 
geometric methods, because it does not provide an estimate of the interaction energy or van der 
Waals forces, methods with different levels of difficulty and computational costs [Miranker, 
1991]. Furthermore, MOE’s Site Finder does not use grids [Hendlich 1997] and its method is 
more efficient in terms of both memory use and CPU use. Finally, the MOE approach 
estimates the relative positions and accessibility of the receptor atoms very effectively and uses 
hydrophobic/hydrophilic classification to separate water sites from the more likely 
hydrophobic sites [Labute 2001]. 
The analysis of LCAT through the MOE Site Finder module revealed 27 putative binding sites; 
the top-scoring contained 346 contact atoms, among which 73 were hydrophobic and 256 
involved sidechain atoms. 
As can be seen in Figure 3.7, the identified binding pocket has all the expected features. The 
binding pocket is quite large, able to bind at the same time both the reaction substrates; it has 
hydrophobic features, and the catalytic triad faces the binding site, but is not fully solvent-
exposed. In detail, from the figure, we can see that the binding pocket is divided into two 
hydrophobic regions (in yellow), separated by a thin, more exposed region (in blue). 
 
In most lipases, it has been reported that a mobile lid covers the substrate binding site, and 
enzyme activation occurs upon binding to a hydrophobic substrate interface. In detail, in water, 
the access channel to the active site is closed by lid, and it opens only upon binding to a 
hydrophobic interface. Usually, the lid consists of a single short helix, and it is closed onto the 
active site. In contrast to the core of lipases, whose architecture is highly conserved, lids are 
less conserved elements, with significant variations in their length and different relative 
positions in the various lipases. In LCAT, several experiments have pointed out a highly 
amphipathic region: an α -helix in the N-terminal domain, closed, as in other lipases, by a 
disulphide bridge (Cys 50–Cys 74) [Peelman 1999]. This region is identified as an interfacial 
recognition domain for (apo)lipoproteins, and it could not only serve as a binding site for the 
hydrophobic substrate but further include a ‘tilted’ peptide, which is thought to destabilize the 
lipid substrate and facilitate the diffusion of a monomeric phospholipid or triglyceride into the 
active site cavity of the enzyme [Peelman 1997]. 
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Figure 3.7. LCAT binding site identified by MOE’s Site Finder. The alpha spheres are depicted in the whole LCAT 
structure, whereas in the right panel the molecular surface of LCAT active site is shown (hydrophobic regions in 
yellow, and solvent-exposed regions in blue). 
 
This region is very distant from the enzyme active site, which is in the core of the protein – a 
region that is more conserved and easier to model. In our model we cannot properly define the 
N-terminal domain, because it is not sufficiently conserved, and because this common/shared 
lid is completely folded only in lipid environments. 
 
Mutations mapping 
Mutations in the LCAT gene cause both FLD and FED syndromes, both characterized by very 
low levels of HDL. 
The new enzyme structure is a key to classify LCAT mutations on the basis of their effects on 
enzyme structure and function, and to define the genotype-phenotype relationship in carriers of 
LCAT mutations. Noteworthy demonstrations of how molecular modeling can be successfully 
used to predict the functional importance of specific amino acids and their mutations are 
reported in [Campbell 2007; Peelman 2001; Razzaghi 2001; Kobayashi 2002]. 
Mapping mutations on the new LCAT model may be useful to understand at a molecular level 
FED/FLD differences, and can allow predicting the impact of newly identified mutations on 
LCAT structure and function. 
 
Among the different mutations described in the literature and collected at 
http://www.lcat.it/database.html, we focused our attention on 12 missense mutations, listed in 
Table 3.2. We discarded the mutation Thr (-13) Met, since it occurs in the signal peptide and 
does not directly affect LCAT three-dimensional structure. 
All the listed missense mutations involve residues that are highly conserved in the LCAT 
sequence of vertebrate species for which LCAT primary structure is known. 
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It is important to note that our dataset includes two mutations affecting the same amino acid, 
but determining the two alternative pathologies. 
 
Table 3.2. List of LCAT mutations and linked pathologies. 
 
Mutant Mutant phenotype 
T-13M FED 
V46E FED 
A141T FED 
R244H FED 
T274A FED 
S91P FLD 
R140C FLD 
R147W FLD 
S181N FLD 
K218N FLD 
T274I FLD 
V309M FLD 
L372R FLD 
 
As reported in Figure 3.8, mutations don't cluster by disease but are spread over all the LCAT 
structure; it turns then impossible to topologically define a region responsible for FED and 
another for FLD. 
 
 
 
Figure 3.8. Mapping of LCAT mutations. In yellow residues involved in FED, in red those involved in FLD, in orange 
T274. 
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As a first approach to evaluate the impact of mutations on LCAT, we used two prediction tools 
available online: Polyphen (polymorphism phenotyping) [Adzhubei 2010] and PANTHER 
(Protein ANalysis THrough Evolutionary Relationships) [Thomas 2006]. Both are based on 
homology sequence analysis and on the evaluation of the physico-chemical properties of the 
amino acids, and use a machine-learning approach. 
Polyphen predictions rely on physical and comparative considerations that estimate the impact 
of an amino acid replacement on the three-dimensional structure and on the function of the 
protein. Instead, PANTHER estimates the probability of a deleterious functional effect due to a 
given coding variant (Pdeleterious scores) by measuring substitution position-specific 
evolutionary conservation among evolutionarily-related proteins, without offering an explicit 
provision whether or not a mutation is possibly disease-causing but only yielding a probability 
evaluation. 
As reported in Table 3.3, either tool produces a different output. Polyphen predicts all the test 
mutations as potentially damaging, except S91P and L372R, which are indicated as possibly 
damaging; this sorting is not useful to correctly classify the mutations that determine either 
FED or FLD diseases. 
Conversely, PANTHER appears to be able to discriminate among the mutations those with a 
more severe impact on the carriers, with an average of 0.668 [pdeleterious] for FED mutations 
and 0.874 [pdeleterious] for FLD mutations. 
 
Then, we analyzed in detail the effects of FED and of FLD mutations on LCAT three-
dimensional structure. LowMode simulations of the wild-type and of the mutated protein were 
run to evaluate the impact of each mutation on the structure of the protein around the mutated 
residue. 
For each structure, potential energy and distance from the reference structure were evaluated, 
constructing a RMSD matrix for each mutation. We analyzed each RMSD matrix to understand 
the impact of the mutation on the structure, checking if the mutation was able to destabilize the 
environment (increase in RMSD), with or without impact on the overall structure of the 
enzyme. The structures, scored for potential energy, are plotted in the RMSD matrices, in 
which structures with low RMSD (from 0.0 to 2.0 Å) are color-coded in blue, while structures 
with high RMSD (from 2.5 to 4Å) are color-coded in red. 
 
All the results produced are summarized in Table 3.3. 
 
Val 46 Glu 
Val 46 has a pivotal role in a hydrogen-bond network involving also Asp 44, Trp 48 and Trp 
75, and is located in a region pointed out as responsible for lipoprotein interaction. Mutation of 
Val 46 into Glu sharply reduces the environment hydrophobicity. However, mutation does not 
seem to destabilize the hydrogen bond network. The mutation modifies the local structural 
environment, but does not seem to affect the global structure of the protein and its activity. 
LowMode simulation doesn’t show any significant modification in the stability of the 
environment around the mutation. 
 
Ala 141 Thr 
Ala 141 is located in the central β-sheet, a critical region for LCAT structure; its mutation into 
Thr changes significantly the environment, making it more hydrophilic. This mutation 
introduces a bigger residue, which bumps on the adjacent amino acids. Minimizing the mutated 
structure, the energy becomes less favorable, going from -10329 Kcal/mol to -6574 kcal/mol, 
and the β-strand starts to unfold. In contrast with these observations, during the LowMode 
simulation no significant differences in behavior are detected versus the wild-type protein. 
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Arg 244 His 
Arg 244 has a pivotal role in a hydrogen bond network involving also Glu 149, Lys 240 and 
Thr 248. Mutation doesn’t break the hydrogen bonds network, but LowMode simulation shows 
a significant decrease in stability of the mutation environment. 
 
Thr 274 Ala  
Thr 274 is close to Phe 103, which contributes to the definition of the oxyanion hole (2.5 Å), 
and its mutation into Ala increases the environment hydrophobicity. We can assume that the 
local conformational rearrangement due to the mutation causes a change in the Phe 103 side 
chain orientation. Also in this case, LowMode simulation shows a significant decrease in 
stability in the mutated amino acid environment.  
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Figure 3.9. LowMode MD output. In figure are reported the FED mutations and the RMSD matrix for each mutation; 
in blue structure with low RMSD (from 0.0 to 2.0 Å), and in red structures with high RMSD (from 2.5 to 4Å). 
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FLD mutations determine a greater impact on LCAT structure: 
 
Ser 91 Pro 
Ser 91 is involved in a hydrogen-bond network also including Asp 136 and Lys 173. Mutation 
of Ser 91 increases the environment hydrophilicity and breaks the hydrogen-bond with Lys 
173, impairing the α-helix structure around this residue. 
 
Arg 140 Cys 
Arg 140 has a pivotal role in a hydrogen bond network involving also Tyr 83, Thr 138, and Val 
139. Mutation of Arg 140 changes this environment, increasing the hydrophilicity and breaking 
the hydrogen bond network. This rearrangement produces the loss of an important network of 
structural interactions. 
 
Arg 147 Trp 
Arg 147 is involved in a hydrogen bond network with Ser 255, Trp 259, Pro 260 and Asp 262. 
With the change from a charged/basic hydrophilic to an aromatic hydrophobic amino acid, this 
mutation alters the environment and impairs the hydrogen bond network. In addition, Trp 
bumps on Lys 159, determining a wide distortion of the local structure. 
 
Ser 181 Asn 
Ser 181 plays a direct role in the catalytic activity of LCAT. Any mutation of this amino acid 
completely blocks LCAT enzymatic activity. 
 
Lys 218 Asn 
Lys 218 is involved in a hydrogen-bond network with Val 222, Thr 334, and Pro 336. This 
mutation modifies the environment, since the residue changes from a charged/basic to a non-
charged amino acid. In addition, we observed that this mutation produces the disruption of the 
local hydrogen-bond pattern. LowMode MD simulation shows a significant decrease in 
stability around the mutation. 
 
Thr 274 Ile 
As described for the FED mutation, in which the same residue is involved, Thr 274 is very 
close to Phe 103 (the oxyanion hole), and its mutation can modify the side chain conformation 
of Phe 103, determining a local conformational rearrangement. Ile is associated with a bigger 
steric bulk than Ala, and this can cause a wider local rearrangement, moving the Phe 103 side 
chain almost completely into the binding pocket, and thus blocking LCAT enzymatic activity. 
Indeed, no room remains for the stabilization of the tetrahedral intermediate typical of this 
trans-esterification reaction. LowMode MD simulation shows in the mutated environment a 
reduction of local flexibility. 
 
Val 309 Met 
Val 309 mutation into Met causes Met to bump on Leu 191. This modifies the local protein 
structure in a region very close to the catalytic site. 
 
Leu 372 Arg 
Leu 372 is involved in a hydrogen bond network with Gly 275 and Ser 236. Its mutation 
modifies the environment, since a neutral hydrophobic amino acid is substituted with a charged 
hydrophilic residue, impairing the hydrogen bond network. Leu 372 is located in the binding 
pocket, in which changes in local hydrophobicity can seriously impair the molecular 
recognition of LCAT substrates. 
  LCAT Structure 
	  68	  
 
 
Results and Discussion  
	   69 
 
 
Figure 3.10. LowMode MD output. The FLD mutations are reported together with the RMSD matrix for each of them; 
structures with low RMSD (from 0.0 to 2.0 Å) are in blue, structures with high RMSD (from 2.5 to 4Å) are in red. 
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Table 3.3. Evolutive and energetic results about heterozygous LCAT mutations, obtained with different approaches: Panther, Polyphen and 
Lowmode MD. 
 
Mutant Phenotype Description Panther results [P deleterious] 
Polyphen 
results  Lowmode results 
T-13M FED Mutation occurs in the signal peptide    
V46E FED Mutation makes environment more hydrophilic 0.474 Probably damaging  no significant differences 
A141T FED Mutation make environment more hydrophilic 0.551 Probably damaging no significant differences 
R244H FED Mutation make environment less hydrophilic 0.794 Probably damaging 
local effect (decrease in 
stability) 
T274A FED Mutation causes local conformational rearrangement due to a change in the Phe103 side chain orientation 0.853 
Probably 
damaging 
local effect (decrease in 
stability) 
S91P FLD Mutation causes impairing of α-helix structure 0.808 Possibly damaging 
global effect (reduction of 
local flexibility) 
R140C FLD Mutation produces the loss of an important network of structural interactions. 0.890 
Probably 
damaging no significant differences 
R147W FLD 
Mutation changes the environment, passing from a 
charged hydrophilic to an aromatic hydrophobic amino 
acid, and impairs the hydrogen network 
0.998 Probably damaging no significant differences 
S181N FLD Any mutation of this catalytic amino acid completely blocks the enzymatic activity. 0.989 
Probably 
damaging no significant differences 
K218N FLD Mutation impairs the hydrogen-bond network 0.905 Probably damaging 
local effect (decrease in 
stability) 
T274I FLD Mutation causes wider local rearrangement than the T274A mutation 0.934 
Probably 
damaging 
local effect (reduction of 
local flexibility) 
V309M FLD Mutation alters structure very close to the catalytic site 0.597 Probably damaging no significant differences 
L372R FLD Mutation alters local hydrophobicity and hydrogen-bond network in the binding pocket 0.871 
Possibly 
damaging no significant differences 
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3.4	  	   CONCLUSIONS	  (Theme	  1)	   
	  
The solution of target structures by physicochemical methods is the best choice, when it can be 
pursued, but frequently severe experimental limitations make this way unsuitable both in the 
evaluation of protein structure-function relationships and in the deployment of a drug discovery 
project. 
LCAT, as already explained in this thesis, is considered a very interesting but difficult target, 
and the very scanty number of published papers about its molecular structure demonstrates this. 
The use of the most up-to-date molecular modeling tools, however, allowed us to achieve 
interesting results in terms of structural knowledge. The combination of distant homology 
modeling, based on different templates, in order to model the protein core with a completely de 
novo three-dimensional structure prediction, and the merging of all the data coming from these 
procedures allowed us to build the first complete model for LCAT structure. This model, which 
satisfies all the published experimental data, was useful to localize and explain the effects of 
mutations identified in patients affected by LCAT genetic deficiencies with more reliability 
with respect to classical bioinformatics methods. Furthermore, the good agreement between the 
predicted and the clinical evidence helped us to validate the quality of the computed LCAT 
model. The usefulness of this model is multifaceted; the model can be used to further 
investigate the enzymatic activity of LCAT, to localize and evaluate the impact of newly 
identified mutations, and to develop new LCAT targeting strategies. 
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3.5	  	   	  LCAT	  MODULATORS	   
 
As recalled under “Introduction”, a number of experimental data on mutated LCAT genotype 
suggest that the presence of defective LCAT might not preclude cholesterol removal from the 
arterial wall and efficient reverse cholesterol transport, despite low HDL levels [Degoma 
2011]. Indeed, two recent studies have shown that low LCAT plasma levels are not associated 
with increased atherosclerosis risk in the general population and that higher LCAT levels are 
associated with an increased cardiovascular risk in women [Holleboom 2010; Baldassarre 
2010]. 
However, till now, the idea of partially inhibiting LCAT activity with targeting molecules has 
never been put to a test. We are aware that LCAT inhibition can exert negative effects on 
plasma HDL concentration, but we believe that, on the other hand, it will have positive effects 
on HDL structure and function. In particular, the inhibition of LCAT activity will produce 
smaller HDL particles, which are more efficient both in cholesterol egress and in inhibiting the 
endothelial expression of cell adhesion molecules, with positive consequences for arterial 
protection. 
To identify molecules able to specifically and selectively decrease LCAT activity, we followed 
two different strategies: an in silico high-throughput screening and an in situ drug design. 
The first strategy is nowadays considered to be the best method for rapid identification of lead 
structures; it consists in a virtual and automatic evaluation of very large libraries of drug-like 
compounds [Ekins 2007]. The second strategy is the rational design of a molecule that mimics 
the II reaction intermediate, and that it is able to block LCAT, fully and selectively occupying 
its active site [Gomeni 2001; Noble 2000]. 
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3.6	  	   	  MATERIALS	  AND	  METHODS	  (Theme	  2)	   
 
Molecular database preparation 
The Asinex Platinum Collection (http://www.asinex.com/ download-zone.html) is a lead-like 
structural library containing approx. 130 000 in-house synthesized compounds. The SD file 
containing all the structures was downloaded and the MOE Conformation Import module was 
run on this file to produce a single low-energy conformation for each putative ligand contained 
in the Asinex SD file. 
 
Molecular docking 
The in silico screening was carried out with the Dock program contained in the MOE 
Simulation module. The full LCAT structure was set as Receptor. Before starting with the 
placement procedure, 1000 conformations were generated for each ligand by sampling their 
rotable bonds. The selected placement methodology was Triangle Matcher, in which the poses 
are generated by superposing triplets of ligand atoms and triplets of receptor site points. The 
protein site points are alpha spheres centers that represent locations of tight packing. Before 
scoring all the generated poses, duplicate complexes were removed. Poses are considered as 
duplicates if the same set of substrate-enzyme atom pairs are involved in hydrogen-bond 
interactions and the same set of ligand atom-protein residue pairs are involved in hydrophobic 
interactions. The accepted poses were scored according to the London dG scoring, which 
estimates the free energy of binding of the ligand from a given pose: 
 ∆𝐺 = 𝑐 +   𝐸!"#$ + 𝑐!"𝑓!"!!!"#$% + 𝑐!𝑓! +!!!"# ∆𝐷!!"#$%_!  
(3.1) 
where c represents the average gain/loss of rotational and translational entropy; 𝐸!"#$ is the 
energy due to the loss of flexibility of the ligand (calculated from ligand topology only); 𝑓!" 
measures geometric imperfections of hydrogen-bonds and takes a value in [0,1]; 𝑐!" is the 
energy of an ideal hydrogen-bond; 𝑓! measures geometric imperfections of metal ligations and 
takes a value in [0,1]; 𝑐! is the energy of an ideal metal ligation; and 𝐷! is the desolvation 
energy of atom i. The difference in desolvation energies is calculated according to: 
 ∆𝐷! = 𝑐!𝑅!! 𝑢 !!𝑑𝑢 −  !∉!∪! 𝑢 !!𝑑𝑢  !∉!  
(3.2) 
where A and B are the protein and/or ligand volumes with atom i belonging to volume B; 𝑅! is 
the solvation radius of atom i (taken as the OPLS-AA van der Waals sigma parameter plus 0.5 
Å ); and 𝑐! is the desolvation coefficient of atom i. The coefficients {𝑐, 𝑐!", 𝑐!, 𝑐!} have been 
fitted from approx. 400 X-ray crystal structures of protein-ligand complexes with available 
experimental pKi data. Atoms are categorized into about a dozen atom types for the assignment 
of the 𝑐! coefficients. The triple integrals are approximated using Generalized Born integral 
formulas. 
 
Only the top scoring solution was kept and submitted to a further refinement step, based on 
molecular mechanics (MM). In order to speed up the calculation, residues over a 6 Å cut-off 
distance away from the pre-refined pose were ignored, both during the refinement and in the 
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final energy evaluation. All receptor atoms were held fixed during the refinement. During the 
course of the refinement, solvation effects were calculated using the reaction field functional 
form for the electrostatic energy term. The final energy was evaluated using the MMFF94x 
forcefield with the Generalized Born solvation model (GBIV) [Wojciechowski 2004]. 
All the ligands contained in the Platinum library were screened according to the above 
procedure. The six top scoring compounds were resubmitted to the same docking procedure, 
keeping for each of them 300 poses. All of them were eventually bought from Asinex and 
tested in in vitro and in vivo experiments. 
The same accurate docking procedure was applied to ‘stirpex’ (see in the following). 
The estimated binding affinities and ligand efficiencies were calculated through the MOE LigX 
module. The pKi were computed through the binding free energies estimated with the London 
dG scoring function. 
 
 
Protein ligand interaction fingerprints (PLIF) 
PLIF is a method for summarizing the interactions between ligands and proteins using a 
fingerprint scheme. Hydrogen-bonds, ionic interactions, and surface contacts are classified 
according to the residue of origin, and built into a fingerprint scheme that is representative of a 
given database of protein::ligand complexes. All the 300 poses for the six selected compounds 
were submitted to the MOE PLIF program in its default configuration, except for the non-
specific surface contacts which were disregarded; this generated a barcode plot summarizing 
the amino acid involvement in protein::ligand interactions. 
 
In vitro and in vivo data 
CER - cholesterol esterification rate 
The esterification of cholesterol within endogenous lipoproteins (cholesterol esterification rate 
[CER]) or incorporated into an exogenous standardized substrate (LCAT activity) was 
determined as previously described [Calabresi 2005]; [Murakami 1995]; [Franceschini 1990]. 
Plasma LCAT concentration was measured by an immuno-enzymatic assay [Murakami 1995]. 
 
Selectivity tests (trypsin/lipases/ACAT) 
Trypsin inhibition was assessed by measuring the proteolytic activity of trypsin on a sensitive 
substrate (apoA-I) by SDS-PAGE [Ji & Jonas 1995]. 
The inhibition of lipase was evaluated with a colorimetric enzymatic assay, using the automatic 
analizer Cobas 8000 Hitachi (Roche Diagnostics). 
 
Inhibition of acilCoA:cholesterol-acyltransferase (ACAT), an enzyme that catalyses 
esterification of cholesterol in cells and that has the same substrates as LCAT, was evaluated in 
peritoneal murine macrophages by measuring the esterification of oleic acid labelled with 14C 
[Bernini 1997]. 
 
In vivo tests 
C57BL mice have treated intraperitoneally with stirpex at a dose of 150 mg/kg. Blood samples 
were collected at different times after treatment [Zanotti 2011]. Plasma LCAT activity was 
measured by CER assay. 
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3.7	  	   	  RESULTS	  AND	  DISCUSSION	  (Theme	  2)	   
 
High-Throughput Screening results 
We carried out the docking procedure in two steps: i) quick docking and ii) accurate docking 
(Figure 3.11). To evaluate the docking results in the refinement step of the procedures, we run 
molecular mechanics computations, and computed the final energy score with an empirical 
scoring function based on the MMFF94x forcefield with the generalized Born implicit 
solvation model (MM/GBIV). 
We followed this procedure because the London dG function used after the ligand placement 
step does not take into account the van der Waals repulsive forces and, as such, only produced 
results with a favorable negative energy. Furthermore, since the molecular mechanics 
refinement step is based on the MMFF94x forcefield, it was more consistent to score the poses 
according to the same forcefield used during the calculations. 
 
 
 
Figure 3.11. Complete docking pipeline. 
 
All ligands in the tested Asinex database were evaluated using the quick docking procedure, 
refining and keeping only the best solution for each ligand. Figure 3.12 shows the MM/GBIV 
energy score plot for the 100 best docking solutions. 
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Figure 3.12. Plot of MM/GBIV energy score for the 100 best docking solutions. 
 
The ligands corresponding to the six best poses show binding scores between -30.90 and -29.02 
kcal/mol; these six compounds were submitted to the accurate docking procedure, generating 
300 solutions (poses) for each ligand. 
Figure 3.13 shows the plot of the binding energies for all the obtained solutions, sorted per 
molecule. 
 
 
 
Figure 3.13. Plot of binding energies for the six best compounds, sorted per molecule. 
 
Figure 3.14 reports the chemical structures of the six top-scoring compounds. They belong to 
different chemical classes, suggesting that the in silico screening allowed us to identify putative 
lead compounds with quite different chemical properties. In figure, the best poses of the 
selected compounds are reported. The active molecules completely block the access to the 
LCAT active site, even if they are located not very deeply in its binding pocket.  
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Figure 3.14, Chemical structures of the six top-scoring compounds and the corresponding lowest energy pose of these 
compounds interacting with LCAT binding site. 
 
Table 3.4 reports some physico-chemical parameters for the selected ligands. The reported pKi 
values (-Log dissociation constant) are computed through the London dG scoring function and 
the Lig X MOE module, after a further refinement of the docked complexes. This and other 
empirical scoring functions are useful to rank the complexes according to their dissociation 
constant, as already discussed by Eberini et al [Eberini, 2011]. The docking score of the poses 
according to the MM/GBIV and the pKi values (affinities) computed through the London dG 
scoring function show a similar trend, suggesting that both these methods, based on different 
approaches, can be used to evaluate docking results and to compute approximate binding free 
energies for the system under investigation. 
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Table 3.4. Physico-chemical parameters for the six top-scoring ligands. 
 
Ligand MM/GBIV  
docking score (kcal/mol) 
Affinity 
(pKi) 
#1   ASN 00867702 -30.38 6.75 
#2   ASN 03653603 -23.04 7.88 
#3   ASN 04886753 -26.58 6.62 
#4   ASN 05214098 -24.23 6.54 
#5   ASN 07438920 -27.87 6.46 
#6   ASN 10813898 -24.77 6.18 
 
 
The PLIF barcode plot (Figure 3.15) analyzes all the poses from the docking refinement step 
for the six top-scoring compounds. Twenty-three amino acids are recognized as relevant in the 
interaction between LCAT and these compounds. Most of the residues positive to PLIF 
analysis belong to the set of amino acids previously identified by the MOE Site Finder module; 
exceptions are Leu 221, Glu 241, Arg 244, and Ile 326. 
Gly 104, Glu 242, Ile 245, Tyr 327, and Phe 331 are the residues associated with the highest 
number of interactions with the tested ligands; all residues face the active site pocket. 
 
 
Figure 3.15. PLIF barcode plot. Each line corresponds to a ligand-LCAT interaction. 
 
Observing in detail the identified molecules, these can be grouped into two distinct chemical 
families. 
Family (I) contains compound 2 (ASN 03653603) and 3 (ASN 04886753), and has the general 
formula in Figure 3.16. 
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Figure 3.16. General formula for ASN 03653603 and ASN 04886753; where R is selected from the group comprising 
aryl, alkyl, benzyl optionally substituted; R1 is an optionally substituted aryl; R2 is selected from H, alkyl, F, Cl, Br, I; 
R3 and R4 are independently selected from the group comprising H, aryl, alkyl, benzyl optionally substituted, or R3 
and R4 are closed to form a carbo- or hetero-cycle optionally substituted. In a preferred form, R is selected from aryl or 
benzyl optionally substituted in the para position; still more preferably, R is phenyl or methylphenyl substituted in the 
para position; R1 is an optionally substituted phenyl or a heteroaryl, still more preferably R1 is a thiophene; R2 is H or 
F; R3 and R4 are closed to form a hetero-cycle optionally substituted. 
 
Family (II) collects compound 1 (ASN 00867702), 4 (ASN 05214098), 5 (ASN 07438920) and 
6 (ASN 10813898), and has the general formula in Figure 3.17. 
 
R1
S
Y
S
R2
R
R3
R4
R5  
 
Figure 3.17. General formula for ASN 00867702, ASN 05214098, ASN 07438920 and ASN 10813898; where R, R3, 
R4, R5 can be independently present or absent, and when present, R, R3, R4, R5 are O, R1 and R2 are independently 
selected from alkyl or aryl optionally substituted, Y is an alkyl chain, aryl, alkyl -aryl optionally substituted and 
optionally containing heteroatoms or Y is a phenyl. One of these forms is the compound 6. 
In a preferred form, R1 is alkyl and R2 is aryl, wherein said aryl is preferably in a chain to 8 carbon atoms. Even more 
preferably, said compound is selected from 1 long C8 or 5C8. 
In a further embodiment, R, R3, R4, R5 are absent, R1 is p-methoxy benzyl-X, where X is a hetero aryl mono, bi or tri-
substituted, and R2 is p-benzilmetossi Z, where Z is a hetero aryl mono, bi-or tri-substituted. Preferably, X and Z are 
equal to each other.  
 
De novo design results 
Once obtained the structural model of LCAT and clearly defined the molecular mechanism of 
the reaction catalysed, we designed a compound capable of acting as irreversible inhibitor of 
the enzyme, and useful as a laboratory pharmacological tool. 
To design such an inhibitor while achieving the highest selectivity, we set to mimic the II 
intermediate of the reaction catalysed by the enzyme - a compound in which a cholesterol 
molecule and a fatty acid are bound together. Indeed, the I reaction intermediate could be 
similar for other enzymes that share the same catalytic triad, and this would certainly result in a 
loss of selectivity [Grochulski 1994]. 
For this reason, we designed a compound joining a molecule of cholesterol with a phosphonyl 
chloride group to a 17-carbon atom chain, an optimal length for the functionality of LCAT. 
This resulted in the synthesis of a heptadecylcholesteryl-(R,S)-phosphonyl chloridate, a 
compound that is able to fully occupy the active site of LCAT as identified in our in silico 
model (Figure 3.18) [Yang 1998]. 
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Figure 3.18. Chemical structures of the heptadecylcholesteryl (R, S) phosphonyl chloridate and corresponding lowest 
energy pose in LCAT binding site 
 
Since this molecule has a chiral centre, both the enantiomers were tested in silico, and 
computational data suggested that the R-enantiomer is energetically favoured. 
Henceforth, for convenience, we shall call "stirpex" the racemic mixture of 
heptadecylcholesteryl phosphonyl chloridate. 
The binding energy of this molecule to LCAT (disregarding the covalent bond) was measured 
in silico, using the molecular docking protocol reported and the binding score is -29.40 
kcal/mol. 
Analyzing the docking results, we can recognize two distinct pocket portions able to bind: i) 
the cyclopentanoperhydrophenanthrene nucleus and ii) the long-chain fatty acid. As previously 
mentioned, both these regions are strongly hydrophobic. 
 
In vitro and in vivo results 
The ability to affect the cholesterol esterification process of the identified LCAT inhibitors 
(both the HTS molecules and stirpex) was assessed in vitro by the measurement of the 
cholesterol esterification rate (CER) in control human plasma. In this experiment, modulators 
were added to control plasma and standardized substrates at different concentrations, and CER 
and LCAT activity were measured. On the basis of the concentration-response curve obtained 
in vitro, the appropriate in vivo dose for stirpex was then established. 
Figure 3.28 reports the dose-response curves of stirpex for the activity and selectivity assays 
versus ACAT, trypsin and lipase. 
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Figure 3.19. Dose-response curves of stirpex for the activity and selectivity assays vs LCAT (blue) ACAT (red), 
trypsin (green) and lipase (purple). 
 
Figure 3.20 reports the dose-response curves of the Asinex compounds for the activity and 
selectivity assays versus ACAT and trypsin. 
 
It is clear that all the molecules are able to completely inhibit the enzyme, although at different 
concentrations. All Asinex molecules completely inhibit LCAT at a concentration of 73 nmol, 
while stirpex only at 660 nmol. These results validate the computational model of LCAT three-
dimensional structure: all the selected molecules are able to effectively interact with LCAT 
binding site. 
 
We also performed selectivity tests for all the compounds versus other enzymes: one able to 
catalyze the formations of cholesterol esters, sterol O-acyltransferase 1 (ACAT), another able 
to hydrolyze proteins, trypsin. Stirpex was also tested versus a human lipase that shares with 
LCAT the same catalytic triad. 
As reported in Figure 3.19, stirpex inhibits only LCAT, thus showing to be highly selective; 
this result indirectly confirms the quality of the active site model at an atomic level, since the 
compound was designed with high complementarity with respect to the active site modelled for 
LCAT. 
As reported in Figure 3.20, all the molecules identified through HTS are unable to bind trypsin, 
and appear selective against other α/β hydrolases. 
Compound 1 (ASN00867702) is slightly soluble and was not tested in vitro. 
 
 
  LCAT Modulators 
	  84	  
 
Figure 3.20. Dose-response curves of the six top-scoring compounds for the activity and selectivity assays vs LCAT 
(blue) ACAT (red), and trypsin (green). 
 
However, some among the Asinex compounds, specifically compound 3 (ASN04886753) and 
2 (ASN 03653603), can also inhibit ACAT. These compounds are thus incompletely selective, 
and were discarded without submitting them to the following analysis step. Compound 4 
(ASN05214098) and 6(ASN10813898) showed limited inhibitory activity of ACAT, just at 
very high concentrations, and can therefore be defined as LCAT selective inhibitors. 
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In order to test the ability of our compounds to inhibit LCAT in vivo, an inhibition assay was 
carried out in the C57BL mouse model. Murine LCAT is highly similar to human (86% 
identity). Seven mice were treated intraperitoneally with stirpex at a dose of 150 mg/kg. Blood 
samples were collected at different times after treatment, and LCAT activity in plasma was 
evaluated. The time-course of the inhibition assay is summarized in Table 3.5. 
For the time being, stirpex is the only LCAT inhibitor tested in vivo. 
 
Table 3.5. Syrpex in vivo inhibition assay. 
 
 LCAT activity 
(0h) 
nmol CE/ml/h 
LCAT activity 
(6h) 
nmol CE/ml/h 
LCAT activity 
(30h) 
nmol CE/ml/h 
LCAT activity 
(45h) 
nmol CE/ml/h 
Mouse 1  6.0 0.0  
Mouse 2  7.5 0.0  
Mouse 3  7.0 0.0  
Mouse 4 6.5  3.3 0.0 
Mouse 5 2.3  2.5 0.0 
Mouse 6 3.1  3.0 0.0 
Mouse 7 6.3  0.0 0.0 
 
The compound is absorbed, distributed and can efficiently bind to, and inhibit, LCAT. 
Complete inhibition occurs between 30 and 45 hours after administration. 
These data further confirm the high specificity of stirpex, whereas the selectivity of some of the 
reversible compounds suggests that the LCAT binding site has been modeled in a sufficiently 
accurate fashion. 
  
  LCAT Modulators 
	  86	  
	  
	  
3.8	   	  CONCLUSIONS	  (Theme	  2)	   
 
The most up-to-date pharmacology strategies for drug discovery require the identification of 
specific targets that play a key role in the development of a specific pathology. The knowledge 
of the structure of the identified putative targets is a necessary step in the drug discovery 
pipeline. Differently, the possibility to modulate/operate the selected targets is assigned to a 
serendipitous process or to the deduction of molecules already in use for the modulation of 
other targets, frequently phylogenetically correlated. These two possibilities are not very 
effective: serendipity efficiency is completely unpredictable, whereas the use of molecules 
coming from the pharmacology of other targets generally fails in term of specificity and 
selectivity. 
Recently, molecular modeling has made available a set of approaches, methods and tools 
useful to successfully manage this issue and to increase the structural knowledgebase, 
especially when working with difficult targets. The computational approach can be deployed in 
two different ways: i) the availability of large chemical databases and the computational power 
of the new computers allow a very efficient in silico high-throughput screening starting form 
the target structure and independently from any pharmacophoric hypothesis; ii) on the other 
hand, the knowledge of the active site and of the catalytic mechanism of a target can be 
exploited for de novo computer-aided drug design. 
Our de novo design of an irreversible inhibitor is based on the knowledge of LCAT catalytic 
mechanism. A molecule able to mimic the II reaction intermediate, which is peculiar of LCAT 
and ACAT proteins, can be an interesting pharmacological tool to investigate the effects of 
LCAT inhibition on atherosclerotic disease. Up to now, stirpex is the first specific LCAT 
inhibitor, which does not demonstrate any inhibitory activity on other proteins sharing the same 
catalytic triad. For obvious reasons, stirpex cannot be proposed as a drug. Further 
modifications of this molecule could allow us to identify new active molecules belonging to the 
same chemical family. On the other hand, the high-throughput screening carried out on LCAT 
identified some very potent reversible inhibitors, which can be of some interest in the further 
drug development step. The demonstration that some of the identified molecules are selective 
for LCAT with respect to other Ser/Asp/His proteins, and especially with respect to ACAT 
(which is a very close paralogous protein), suggests that our distant comparative modeling 
strategy allowed us to predict with a good approximation the shape of the enzyme active site. 
We deem that, at the state of the art, molecular modeling has become a necessary and efficient 
approach both to increase the knowledge of newly identified targets and to carry out in a 
rational way the first steps of the long pipeline towards drug discovery in pharmacology. 	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